Digital Locations (DLOC) 10-K 21 Mar 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 21, 2017	Jun. 30, 2016
Document And Entity Information
Entity Registrant Name	Carbon Sciences, Inc.
Entity Central Index Key	1,407,878
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 2,806,147
Entity Common Stock, Shares Outstanding		36,675,123
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,016
Trading Symbol	cabn

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash	$ 39,934	$ 37,696
Prepaid expenses	1,905	2,007
Total current assets	41,839	39,703
Property and equipment, net	1,194	339
Total assets	43,033	40,042
Current liabilities:
Accounts payable	108,381	139,735
Accrued expenses and other current liabilities	5,846	4,611
Accrued interest, notes payable	50,964	285,624
Derivative liabilities	6,690,697	13,184,369
Convertible notes payable	39,917	191,500
Convertible notes payable, net of discount of $358,981 and $222,758, respectively	361,619	1,265,506
Total current liabilities	7,257,424	15,071,345
Long-term liabilities - Convertible notes payable, net of discount of $0 and $159,768, respectively		40,232
Total liabilities	7,257,424	15,111,577
Commitments and contingencies
Stockholders' deficit:
Preferred stock, $0.001 par value; 20,000,000 shares authorized: Series B, 16,155 and 0 shares issued and outstanding, respectively	16
Common stock, $0.001 par value; 2,000,000,000 shares authorized, 35,178,624 and 32,149,790 shares issued and outstanding, respectively	35,179	32,150
Additional paid-in capital	20,400,413	12,268,651
Accumulated deficit	(27,649,999)	(27,372,336)
Total stockholders' deficit	(7,214,391)	(15,071,535)
Total liabilities and stockholders' deficit	$ 43,033	$ 40,042

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Convertible Notes, Current
Convertible promissory notes discount	$ 358,981	$ 222,758
Convertible Notes, Non-Current
Convertible promissory notes discount		$ 159,768

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Statement
Revenue
Operating expenses:
General and administrative	623,515	341,160
Research and development	65,497	298,865
Depreciation	617	208
Total operating expenses	689,629	640,233
Loss from operations	(689,629)	(640,233)
Other income (expense):
Rental income	26,838	29,835
(Loss) gain on settlement of debt	(33,561)	5,660
Gain (loss) on change in derivative liabilities	1,217,339	(3,842,671)
Interest expense	(798,650)	(770,752)
Total other income (expense)	411,966	(4,577,928)
Loss before income taxes	(277,663)	(5,218,161)
Provision for income taxes
Net loss	$ (277,663)	$ (5,218,161)
Net loss per share, basic and diluted	$ (0.01)	$ (0.18)
Weighted average number of shares outstanding, basic and diluted	34,908,588	29,512,353

STATEMENTS OF STOCKHOLDERS' DEF

STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)		Series A Preferred Stock	Series B Preferred Stock		Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total
Stockholders' Equity, beginning of period, Value at Dec. 31, 2014					$ 24,119		$ 11,526,295	$ (22,154,175)	$ (10,603,761)
Stockholders' Equity, beginning of period, Shares at Dec. 31, 2014					24,118,618
Issuance of common stock for conversion of notes payable and accrued interest payable, Value					$ 8,031	[1]	714,356		722,387
Issuance of common stock for conversion of notes payable and accrued interest payable, Shares	[1]				8,031,172
Stock compensation cost							28,000		28,000
Net loss								(5,218,161)	(5,218,161)
Stockholders' Equity, end of period, Value at Dec. 31, 2015					$ 32,150		12,268,651	(27,372,336)	(15,071,535)
Stockholders' Equity, end of period, Shares at Dec. 31, 2015					32,149,790
Issuance of common stock for conversion of notes payable and accrued interest payable, Value					$ 3,028	[2]	83,359		86,387
Issuance of common stock for conversion of notes payable and accrued interest payable, Shares	[2]				3,028,018
Adjustment to shares pursuant to reverse stock split, Value					$ 1		(1)
Adjustment to shares pursuant to reverse stock split, Shares					816
Issuance of Series A preferred shares for services, Value		$ 1							1
Issuance of Series A preferred shares for services, Shares		1,000
Redeem Series A preferred shares, Value		$ (1)							(1)
Redeem Series A preferred shares, Shares		(1,000)
Issuance of Series B preferred shares for conversion, Value			$ 16	[3]			11,630,806		11,630,822
Issuance of Series B preferred shares for conversion, Shares	[3]		16,155
Derivative liability upon issuance of Series B preferred shares							(3,908,211)		(3,908,211)
Related party debt forgiven and contributed to capital							325,809		325,809
Net loss								(277,663)	(277,663)
Stockholders' Equity, end of period, Value at Dec. 31, 2016			$ 16		$ 35,179		$ 20,400,413	$ (27,649,999)	$ (7,214,391)
Stockholders' Equity, end of period, Shares at Dec. 31, 2016			16,155		35,178,624
[1]	8,031,172 shares issued at fair value at $0.055 - $0.135 per share
[2]	3,028,018 shares issued at fair value at $0.028 - $0.029 per share
[3]	Issuance for the conversion of notes payable, accrued interest payable and derivative liabilities with a book value of $11,630,822

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (277,663)	$ (5,218,161)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	617	208
Loss (gain) on settlement of debt	33,561	(5,660)
Amortization of debt discount recorded to interest expense	730,545	619,622
(Gain) loss on change in derivative liabilities	(1,217,339)	3,842,671
Stock compensation cost		28,000
Changes in assets and liabilities:
(Increase) decrease in prepaid expenses	102	68,586
Increase (decrease) in:Accounts payable	(25,910)	(20,535)
Increase (decrease) in:Accrued expenses and other current liabilities	67,480	150,518
Net cash used in operating activities	(688,607)	(534,751)
Cash flows from investing activities:
Purchase of property and equipment	(1,472)
Net cash used in investing activities	(1,472)
Cash flows from financing activities:
Proceeds from convertible notes payable	707,000	557,000
Repayment of convertible notes payable	(14,683)
Net cash provided by financing activities	692,317	557,000
Net increase in cash	2,238	22,249
Cash, beginning of the year	37,696	15,447
Cash, end of the year	$ 39,934	$ 37,696

1. Organization and Line of Bus

1. Organization and Line of Business	12 Months Ended
	Dec. 31, 2016
Notes
1. Organization and Line of Business	1. ORGANIZATION AND LINE OF BUSINESS Organizational History Carbon Sciences, Inc. (the "Company") was incorporated in the State of Nevada on August 25, 2006 as Zingerang, Inc. On April 2, 2007, the Company changed its name to Carbon Sciences, Inc. Overview of Business The Company was initially in the business of offering real-time and interactive mobile communication services to businesses and consumers under the Zingerang trade name. Through two Sponsored Research Agreements ("SRA") with the University of California, Santa Barbara ("UCSB"), we have performed research work to develop graphene-based technologies and devices. Subsequent to December 31, 2016, we entered into our third SRA with UCSB to further develop a graphene-based device (see Note 13). Graphene is a naturally occurring sheet of pure carbon that is only one atom thick. It is flexible, transparent, impermeable to moisture, strong and highly conductive. Experts believe that graphene is a very versatile material that can enable new applications such as bendable touchscreen displays, rapid charge batteries, super-capacitors, low cost solar cells, extreme high-speed semiconductors, biosensors, as well as water purification. If successfully developed and commercialized, we plan to license our graphene technology to other companies. The technology is intended to commercialize graphene for optical modulator applications to potentially enhance the speed and performance of fiber optic systems. On January 5, 2015, Carbon Sciences formed Transphene, Inc., a Nevada corporation ("Transphene"), of which the Company owns 50% of the total issued and outstanding capital stock. The remaining 50% is owned by Dr. Kaustav Banerjee ("Banerjee"), a director and Chief Technical Officer of Transphene. Transphene was formed to commercialize any technology that the Company licensed from UCSB as a result of SRA #1. In consideration for its interest in Transphene, the Company agreed to assign the intellectual property rights acquired by the Company from SRA #1 to Transphene. At this time, the Company does not see an opportunity to commercialize the research findings of SRA #1, has not licensed any intellectual property from UCSB, and therefore has not assigned any intellectual property to Transphene. Therefore, we terminated our joint venture through Transphene and wound up and dissolved Transphene in 2016. There have been no financial transactions in Transphene and no impact on our financial statements. On February 9, 2016, we announced a growth-by-acquisition strategy to extend our presence in the information technology ("IT") market. Going Concern The accompanying financial statements have been prepared on a going concern basis of accounting, which contemplates continuity of operations, realization of assets and liabilities, and commitments in the normal course of business. The accompanying financial statements do not reflect any adjustments that might result if the Company is unable to continue as a going concern. The Company does not generate any revenue, and has negative cash flows from operations, which raise substantial doubt about the Company's ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon, among other things, raising additional capital. Since its inception through December 31, 2016, the Company has obtained funds primarily from the issuance of common stock and debt. Management believes this funding will continue, and is continually seeking new investors. Management believes the existing shareholders and lenders and prospective new investors will provide the additional cash needed to meet the Company's obligations as they become due, and will allow the development of its core of business.

2. Summary of Significant Accou

2. Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Notes
2. Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES This summary of significant accounting policies is presented to assist in understanding our financial statements. The financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements. Revenue Recognition We will recognize revenue when services are performed, and at the time of shipment of products, provided that evidence of an arrangement exists, title and risk of loss have passed to the customer, fees are fixed or determinable, and collection of the related receivable is reasonably assured. To date, we have had no revenues. Cash and Cash Equivalents We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements include the estimate of useful lives of property and equipment, the deferred tax valuation allowance, the fair value of stock options and derivative liabilities. Actual results could differ from those estimates. Property and Equipment Property and equipment are stated at cost, and are depreciated using the straight line method over the following estimated useful lives: Computer equipment 3 Years Machinery and equipment 7 Years Depreciation expense for the years ended December 31, 2016 and 2015 was $617 and $208, respectively. Derivative Liabilities We have identified the conversion features of our convertible notes payable and our Series B preferred stock as derivatives. We estimate the fair value of the derivatives associated with our convertible notes payable using the Black-Scholes pricing model and estimate the fair value of the derivatives associated with our Series B preferred stock using a multinomial lattice model based on projections of various potential future outcomes. We estimate the fair value of the derivative liabilities at the inception of the financial instruments, at the date of conversions to equity and at each reporting date, recording a derivative liability, debt discount, additional paid-in capital and a gain or loss on change in derivative liabilities as applicable. These estimates are based on multiple inputs, including the market price of our stock, interest rates, our stock price volatility, variable conversion prices based on market prices as defined in the respective agreements and probabilities of certain outcomes based on management projections. These inputs are subject to significant changes from period to period and to management's judgment; therefore, the estimated fair value of the derivative liabilities will fluctuate from period to period, and the fluctuation may be material. Fair Value of Financial Instruments Disclosures about fair value of financial instruments require disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2016 and 2015, the amounts reported for cash, accrued interest, accrued expenses and other current liabilities, and notes payable approximate fair value because of their short maturities. We adopted ASC Topic 820 (originally issued as SFAS 157, "Fair Value Measurements") as of January 1, 2008 for financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States, and expands disclosures about fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include: · Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; · Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and · Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows at December 31, 2016 and 2015: Total Level 1 Level 2 Level 3 December 31, 2016: Derivative liabilities $6,690,697 $ - $ - $6,690,697 Total liabilities measured at fair value $6,690,697 $ - $ - $6,690,697 December 31, 2015: Derivative liabilities $13,184,369 $ - $ - $ 13,184,369 Total liabilities measured at fair value $13,184,369 $ - $ - $13,184,369 During the years ended December 31, 2016 and 2015, the Company had the following activity in its derivative liabilities account: Convertible Notes Series B Payable Preferred Stock Total Derivative liabilities at December 31, 2014 $9,476,605 $ - $9,476,605 Addition to liability for new debt issued 557,000 - 557,000 Elimination of liability on conversion (691,907) - (691,907) Change in fair value 3,842,671 - 3,842,671 Derivative liabilities at December 31, 2015 13,184,369 - 13,184,369 Addition to liability for new debt/shares issued 707,000 3,908,211 4,615,211 Elimination of liability on conversion to common shares (33,756) - (33,756) Elimination of liability on conversion to preferred shares (9,750,930) - (9,750,930) Contribution of liability to capital on settlement of related party debt (106,858) - (106,858) Change in fair value (663,919) (553,420) (1,217,339) Derivative liabilities at December 31, 2016 $3,335,906 $3,354,791 $6,690,697 Loss per Share Calculations Basic net income or loss per common share is computed by dividing net income or loss by the weighted average number of common shares outstanding. Diluted net income or loss per common share is computed by dividing net income or loss by the sum of the weighted average number of common shares outstanding and the dilutive potential common share equivalents then outstanding. Potential dilutive common share equivalents consist of shares issuable upon the exercise of outstanding stock options and warrants to acquire common stock using the treasury stock method and the average market price per share during the period, and shares issuable upon exercise of convertible notes payable and convertible preferred stock. Since we had no dilutive effect of stock options and warrants for the years ended December 31, 2016 and 2015, our basic weighted average number of common shares outstanding is the same as our diluted weighted average number of common shares outstanding. For the year ended December 31, 2016, the Company has excluded 1,410,000 common shares for exercisable options, 46,000 common shares for exercisable warrants, approximately 157,269,000 shares issuable upon conversion of convertible notes payable and approximately 367,000,000 common shares upon conversion of convertible Series B preferred stock. For the year ended December 31, 2015, the Company has excluded 1,410,000 common shares for exercisable options, 46,000 common shares for exercisable warrants and approximately 3,738,502,000 shares issuable upon conversion of convertible notes payable. Income Taxes We account for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Research and Development Research and development costs are expensed as incurred. Total research and development costs were $65,497 and $298,865 for the years ended December 31, 2016 and 2015, respectively. Advertising Costs We expense the cost of advertising and promotional materials when incurred. We incurred no advertising costs for the years ended December 31, 2016 and 2015. Stock-Based Compensation Stock-based compensation is measured at the grant date based on the value of the award granted using the Black-Scholes option pricing model, and recognized over the period in which the award vests. For stock awards no longer expected to vest, any previously recognized stock compensation expense is reversed in the period of termination. The stock-based compensation expense is included in general and administrative expenses. Comprehensive Loss Comprehensive loss is the same as net loss for all years presented. Reclassifications Certain amounts in the prior years have been reclassified to conform to the current year presentation. Recently Issued Accounting Pronouncements In January 2017, the FASB issued Accounting Standards Update ("ASU") No. 2017-4, "Intangibles – Goodwill and Other (Topic 350): "Simplifying the Test for Goodwill Impairment." This update simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit's goodwill with the carrying amount of that goodwill. Instead, under the amendments in this update, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. An entity should apply the amendments in this update on a prospective basis. An entity is required to disclose the nature of and reason for the change in accounting principle upon transition. That disclosure should be provided in the first annual period and in the interim period within the first annual period when the entity initially adopts the amendments in this update. A public business entity that is an SEC filer should adopt the amendments in this Update for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company is currently unable to determine the impact on its financial statements of the adoption of this new accounting pronouncement. In January 2017, the FASB issued ASU No. 2017-1, "Business Combinations (Topic 805): Clarifying the Definition of a Business." The amendments in this update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The amendments of this ASU are effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019. The amendments in this Update are to be applied prospectively on or after the effective date. The Company is currently unable to determine the impact on its financial statements of the adoption of this new accounting pronouncement. In October 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-17, "Consolidation (Topic 810): Interests Held Through Related Parties That are Under Common Control." This update amends the consolidation guidance on how a reporting entity that is the single decision maker of a variable interest entity ("VIE") should treat indirect interests in the entity held through related parties that are under common control with the reporting entity when determining whether it is the primary beneficiary of that VIE. The primary beneficiary of a VIE is the reporting entity that has a controlling financial interest in a VIE and, therefore, consolidates the VIE. A reporting entity has an indirect interest in a VIE if it has a direct interest in a related party that, in turn, has a direct interest in the VIE. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently unable to determine the impact on its financial statements of the adoption of this new accounting pronouncement. In August 2016, the FASB issued ASU No. 2016-15, "Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments." This ASU addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently unable to determine the impact on its financial statements of the adoption of this new accounting pronouncement. Although there are several other new accounting pronouncements issued or proposed by the FASB, which the Company has adopted or will adopt, as applicable, the Company does not believe any of these accounting pronouncements has had or will have a material impact on its financial position or results of operations.

3. Capital Stock

3. Capital Stock	12 Months Ended
	Dec. 31, 2016
Notes
3. Capital Stock	3. CAPITAL STOCK At December 31, 2016, the Company's authorized stock consisted of 2,000,000,000 shares of common stock, with a par value of $0.001 per share. The Company is also authorized to issue 20,000,000 shares of preferred stock, with a par value of $0.001 per share. The rights, preferences and privileges of the holders of the preferred stock will be determined by the Board of Directors prior to issuance of such shares. Series A Preferred Stock On February 12, 2016, the Company filed a Certificate of Designation for its Series A Preferred Stock (the "Series A Certificate") with the Secretary of State of Nevada designating 1,000 shares of its authorized preferred stock as Series A Preferred Stock. The shares of Series A Preferred Stock have a par value of $0.001 per share. The Series A Preferred Shares do not have a dividend rate or liquidation preference and are not convertible into shares of common stock. On February 12, 2016, the Board of Directors of the Company authorized the issuance of 1,000 shares of Series A Preferred Stock, par value $0.001 per share, to the Company's President and director, William E. Beifuss, Jr., for services rendered. For so long as any shares of the Series A Preferred Stock remain issued and outstanding, the holders thereof, voting separately as a class, shall have the right, on or after February 12, 2016, to vote in an amount equal to 51% of the total vote (representing a super majority voting power) with respect to any proposal relating to (a) increasing the authorized share capital of the Company, and (b) effecting any reverse stock split of the Company's issued and outstanding shares of capital stock. Such vote shall be determined by the holder(s) of a majority of the then issued and outstanding shares of Series A Preferred Stock. For example, if there are 10,000 shares of the Company's common stock issued and outstanding at the time of such shareholder vote, the holders of the Series A Preferred Stock, voting separately as a class, will have the right to vote an aggregate of 10,408 shares, out of a total number of 20,408 shares voting. Additionally, the Company is prohibited from adopting any amendments to the Company's Bylaws, Articles of Incorporation, as amended, making any changes to the Series A Certificate, or effecting any reclassification of the Series A Preferred Stock, without the affirmative vote of at least 66-2/3% of the outstanding shares of Series A Preferred Stock. However, the Company may, by any means authorized by law and without any vote of the holders of shares of Series A Preferred Stock, make technical, corrective, administrative or similar changes to the Series A Certificate that do not, individually or in the aggregate, adversely affect the rights or preferences of the holders of shares of Series A Preferred Stock. The shares of the Series A Preferred Stock were automatically redeemed by the Company at their par value on a date 90 days after the effective date of the Series A Certificate. Series B Preferred Stock On March 2, 2016, the Company filed a Certificate of Designation for its Series B Preferred Stock (the "Series B Certificate") with the Secretary of State of Nevada designating 30,000 shares of its authorized preferred stock as Series B Preferred Stock. The shares of Series B Preferred Stock have a par value of $0.001 per share. Effective March 3, 2016, the Board of Directors of the Company authorized the issuance of 16,155 shares of Series B Preferred Stock, with a face value of $1,615,500, to holders of convertible promissory notes in the aggregate principal amount of $1,615,362 payable by the Company (the "Prior Notes"), in exchange for the redemption and cancellation of the Prior Notes, including all outstanding principal of $1,615,362 and unpaid interest, which has been accruing at 10% per annum. At the date of conversion, the Prior Notes and accrued interest payable consisted of the following: Effective Date Principal Accrued Interest December 12, 2012 $198,912 $71,929 February 22, 2013 34,450 9,607 May 29, 2013 97,000 27,461 October 7, 2013 58,000 13,609 April 18, 2014 500,000 82,677 October 1, 2014 500,000 50,749 July 13, 2015 227,000 8,498 Total $1,615,362 $264,530 In the conversion, we decreased derivative liabilities related to the convertible debt by $9,750,930, increased Series B preferred stock by $1 and increased additional paid-in capital by $11,630,806. We also increased derivative liabilities related to the Series B preferred stock issued and decreased additional paid-in capital by $3,908,211. On March 2, 2016, the Company filed a Certificate of Designation for its Series B Preferred Stock (the "Series B Certificate") with the Secretary of State of Nevada designating 30,000 shares of its authorized preferred stock as Series B Preferred Stock. The shares of Series B Preferred Stock have a par value of $0.001 per share. The total face value of this entire series is three million dollars ($3,000,000). Each share of Series B Preferred Stock has a stated face value of One Hundred Dollars ($100) ("Share Value"), and is convertible into shares of fully paid and non-assessable shares of common stock ("Common Stock") of the Company. The holders of outstanding shares of the Series B Preferred Stock (the "Holders") are entitled to receive dividends pari passu with the holders of Common Stock, except upon a liquidation, dissolution and winding up of the Company, in which case the Series B Preferred Stock has a preference. Such dividends will be paid equally to all outstanding shares of Series B Preferred Stock and Common Stock, on an as-if-converted basis with respect to the Series B Preferred Stock. The Holders may elect to use the most favorable conversion price for the purpose of determining the as-if-converted number of shares. In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, the Holder of each outstanding share of the Series B Preferred Stock shall be entitled to receive, out of the assets of the Company available for distribution to its shareholders upon such liquidation, whether such assets are capital or surplus of any nature, an amount equal to one hundred dollars ($100) for each such share of the Series B Preferred Stock (as adjusted for any combinations, consolidations, stock distributions, stock splits or stock dividends with respect to such shares), plus all dividends, if any, declared and unpaid thereon as of the date of such distribution, before any payment is made or any assets distributed to the holders of the Common Stock. After such payment, the remaining assets of the Company will be distributed to the holders of Common Stock. If the assets to be distributed to the Holders of the Series B Preferred Stock are insufficient to permit the receipt by such Holders of the full preferential amounts, then all of such assets will be distributed among such Holders ratably in accordance with the number of such shares then held by each such Holder. The sale of all or substantially all of the Company's assets, any consolidation or merger of the Company with or into any other entity or person, or any other corporate reorganization, in which the stockholders of the Company immediately prior to such consolidation, merger or reorganization, own less than fifty percent (50%) of the Company's voting power immediately after such consolidation, merger or reorganization, or any transaction or series of related transactions to which the Company is a party in which in excess of fifty percent (50%) of the Company's voting power is transferred, excluding any consolidation or merger effected exclusively to change the domicile of the Company, is deemed to be a liquidation, dissolution or winding up. The Series B Preferred Stock is convertible into Common Stock. The Holder has the right, at any time, at its election, to convert all or part of the Share Value into shares of Common Stock. The conversion price is the lesser of (1) Fifty Percent (50%) of the lowest trade price of Common Stock recorded on any trade day after December 12, 2012 or (2) the lowest effective price per share granted to any person or entity, including the Holder but excluding officers and directors of the Company, to acquire Common Stock, or adjusted, whether by operation of purchase price adjustment, settlement agreements, exchange agreements, reset provision, floating conversion or otherwise, any outstanding warrant, option or other right to acquire Common Stock or outstanding Common Stock equivalents (the "Conversion Price"). The conversion formula is as follows: The number of shares receivable upon conversion equals the Share Value divided by the Conversion Price. A conversion notice (the "Conversion Notice") may be delivered to Company by any method of Holder's choice (including but not limited to email, facsimile, mail, overnight courier, or personal delivery), and all conversions will be cashless and not require further payment from the Holder. If no objection is delivered from the Company to the Holder, with respect to any variable or calculation reflected in the Conversion Notice, within 24 hours of delivery of the Conversion Notice, the Company will thereafter be deemed to have irrevocably confirmed and ratified such notice of conversion and waived any objection. The Company will deliver the shares of Common Stock from any conversion to the Holder (in any name directed by the Holder) within three (3) business days of Conversion Notice delivery. If the Company is participating in the Depository Trust Company ("DTC") Fast Automated Securities Transfer ("FAST") program, then upon request of the Holder and provided that the shares to be issued are eligible for transfer under Rule 144 of the Securities Act of 1933, as amended (the "Securities Act"), or are effectively registered under the Securities Act, the Company will cause its transfer agent to electronically issue the Common Stock issuable upon conversion to the Holder through the DTC Direct Registration System ("DRS"). If the Company is not participating in the DTC FAST program, then the Company agrees in good faith to apply and cause the approval for participation in the DTC FAST program. The Conversion Price is subject to equitable adjustments for stock splits, stock dividends or rights offerings by the Company relating to the Company's securities or the securities of any subsidiary of the Company, combinations, recapitalization, reclassifications, extraordinary distributions and similar events. No fractional shares of the Common Stock shall be issuable upon the conversion of shares of the Series B Preferred Stock and the Company shall pay the cash equivalent of any fractional share upon such conversion. If the Company fails to deliver shares in accordance with the required time frame, then for each conversion, a penalty of $1,500 per day will be assessed for each day after the third business day (inclusive of the day of the conversion) until share delivery is made. Such penalty may be converted into Common Stock at the Conversion Price or payable in cash, at the sole option of the Holder (under the Holder's and the Company's expectations that any penalty amounts shall tack back to the original date of the issuance of Series B Preferred Stock, consistent with applicable securities laws). In no event will the Holder be entitled to convert any Series B Preferred Stock, such that upon conversion the sum of (1) the number of shares of Common Stock beneficially owned by the Holder and its affiliates (other than shares of Common Stock which may be deemed beneficially owned through the ownership of the unconverted portion of this Series B Preferred Stock or the unexercised or unconverted portion of any other security of the Company subject to a limitation on conversion or exercise analogous to these limitations), and (2) the number of shares of Common Stock issuable upon the conversion of Series B Preferred Stock, would result in beneficial ownership by the Holder and its affiliates of more than 4.99% of the outstanding shares of Common Stock. The limitations on conversion may be waived by the Holder upon, at the election of the Holder, not less than 61 days prior notice to the Company, and the provisions of the conversion limitation shall continue to apply until such 61st day (or such later date, as determined by the Holder, as may be specified in such notice of waiver). Except as required by law, the Holders of Series B Preferred Stock are not entitled to vote, as a separate class or otherwise, on any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting). Each Holder of outstanding shares of Series B Preferred Stock will be entitled, on the same basis as holders of Common Stock, to receive notice of such action or meeting. So long as any shares of the Series B Preferred Stock remain outstanding, the Company will not, without first obtaining the approval (by vote or written consent, as provided by law) of the holders of at least a majority of the then outstanding shares of Series B Preferred Stock voting together as one class: (a) alter or change the rights, preferences or privileges of the shares of the Series B Preferred Stock so as to affect materially and adversely such shares; or (b) create any new class of shares having preference over the Series B Preferred Stock. The Holder has the right, at its sole discretion, to elect a fixed conversion price for the Series B Preferred Stock. The Fixed Conversion Price may not be lower than the Conversion Price. The Company will not, by amendment of its Certificate of Incorporation, bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of the Series B Certificate, and will at all times carry out all the provisions of the Series B Certificate. Common Stock On April 20, 2016, the Company amended its articles of incorporation to reduce the number of authorized shares of common stock from 1,000,000,000 to 100,000,000 and to affect a one-for-ten reverse stock split of its authorized, issued and outstanding shares of common stock. The Company has given retroactive affect for the reverse stock split in all periods presented in the accompanying financial statements. On April 29, 2016, our Board of Directors and the holder of a majority of the total issued and outstanding voting stock of the Company authorized and approved an amendment to the Company's articles of incorporation to increase the number of authorized shares of common stock from 100,000,000 to 2,000,000,000. During the year ended December 31, 2016, the Company issued a total of 3,028,018 shares of common stock at fair value in conversion of $10,450 of convertible promissory notes, accrued interest payable of $3,176 and derivative liability of $33,75. We recognized a loss of $39,005 on conversion of the notes. The Company also increased the number of outstanding common shares by 816 shares pursuant to the reverse stock split, increasing common stock by $1 and decreasing additional paid-in capital by $1. During the year ended December 31, 2015, the Company issued a total of 8,031,172 shares of common stock at fair value in conversion of $29,200 of convertible promissory notes, accrued interest payable of $6,940 and derivative liability of $691,907. We recognized a gain of $5,660 on the conversion of the notes.

4. Stock Options, Warrants and

4. Stock Options, Warrants and Restricted Stock Awards	12 Months Ended
	Dec. 31, 2016
Notes
4. Stock Options, Warrants and Restricted Stock Awards	4. STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK AWARDS Stock Options As of December 31, 2016, the Board of Directors of the Company had granted non-qualified stock options exercisable for a total of 1,410,000 shares of common stock to its employees, officers, and consultants. Stock-based compensation cost is measured at the grant date based on the value of the award granted using the Black-Scholes option pricing model, and recognized over the period in which the award vests, which is generally 25 months. Stock-based compensation expense included in general and administrative expense was $0 and $28,000 for the years ended December 31, 2016 and 2015, respectively. As of December 31, 2016, we had no unrecognized stock-based compensation expense. A summary of the Company's stock option awards as of December 31, 2016, and changes during the year then ended is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contract Term (Years) Aggregate Intrinsic Value Outstanding at December 31, 2015 1,410,000 $0.19 Granted - $- Exercised - $- Forfeited or expired - $- Outstanding and exercisable at December 31, 2016 1,410,000 $0.19 3.72 $- The aggregate intrinsic value in the preceding table represents the total pretax intrinsic value, based on the closing price of our common stock of $0.0254 as of December 31, 2016, which would have been received by the holders of in-the-money options had the option holders exercised their options as of that date. Warrants As of December 31, 2016 and December 31, 2015, the Company had 46,000 common stock purchase warrants outstanding, with an exercise price of $5.00 per share and expiring on various dates in 2017 and 2018.

5. CONVERTIBLE PROMISSORY NOTES

5. CONVERTIBLE PROMISSORY NOTES PAYABLE	12 Months Ended
	Dec. 31, 2016
Notes
5. CONVERTIBLE PROMISSORY NOTES PAYABLE	5. CONVERTIBLE PROMISSORY NOTES PAYABLE Convertible Promissory Note - $299,212 Effective October 24, 2013, the remaining principal balance of certain notes payable totaling $291,443 and accrued interest of $7,769 were combined in a new 10% convertible promissory note in the aggregate amount of $299,212, which originally matured on October 24, 2014. The maturity date was subsequently extended to June 30, 2016. The new note was convertible into shares of our common stock at a conversion price equal to (a) the lesser of $0.06 per share or (b) 50% of the lowest trade price recorded on any trade date after the effective date, or (c) the lowest effective price per share granted to any person through the issuance of securities after the effective date. After conversions to our common stock during 2013 and 2014, and the three months ended March 31, 2016, the note had a principal balance of $198,912. This principal balance and related accrued interest payable of $71,929 were converted into shares of Series B preferred stock on March 3, 2016. Convertible Promissory Notes - Services of $244,452 On December 31, 2012, we entered into 5% convertible promissory notes with three individuals in exchange for services rendered in the aggregate amount of $244,452, including $185,852 with the Chairman of our Board of Directors and our former Chief Executive Officer ("Chairman"). The notes are convertible into shares of our common stock at a conversion price equal to the lesser of $2.00 per share or the closing price per share of common stock recorded on the trading day immediately preceding the date of conversion. We recorded a debt discount of $237,742 related to the conversion feature of the notes, which has been fully amortized to interest expense, along with a derivative liability at inception. One of the notes with a principal balance of $25,980 at December 31, 2016, matured on December 31, 2014 and is currently in default. The maturity date of a second note with a principal balance of $32,619 at December 31, 2016, has been extended to December 31, 2017. On July 27, 2016, we entered into a Settlement and Release Agreement with the Chairman for full extinguishment of the above described convertible promissory note with a principal balance of $185,852, plus accrued interest. We agreed to pay the Chairman $100 in cash and arranged for him to enter into an option agreement with our principal lender and a principal holder of our Series B preferred stock ("Lender") to acquire 225 shares of our Series B preferred stock from the Lender upon the occurrence of certain events defined in the agreement. Due to the related party nature of this transaction, the extinguishments of the note principal of $185,752, accrued interest payable of $33,199 and associated derivative liability of $106,858 were recorded to additional paid-in capital as a contribution to capital totaling $325,809. Convertible Promissory Note - $100,000 During 2013, we received total proceeds of $40,000 pursuant to a securities purchase agreement for the sale of 10% convertible promissory notes in the aggregate principal amount of $100,000. The notes are convertible into shares of our common stock at a price equal to a variable conversion price of the lesser of $0.90 per share or fifty percent (50%) of the lowest trade price recorded after the effective date. The notes were to mature one year from their effective date. The maturity dates were extended to June 30, 2016. We recorded a debt discount of $40,000 related to the beneficial conversion feature of the notes, which has been fully amortized to interest expense. During the three months ended March 31, 2016, $5,550 principal and $1,660 accrued interest payable were converted into shares of common stock and the remaining principal of $34,450 and accrued interest payable of $9,607 were converted into shares of Series B preferred stock on March 3, 2016. Convertible Promissory Note – Accounts Payable of $29,500 On March 14, 2013, we entered into a 5% convertible promissory note in the principal amount of $29,500, which is convertible into shares of our common stock at a conversion price equal to the lesser of $1.50 per share or the closing price per share of common stock recorded on the trading day immediately preceding the date of conversion. The note matured two years from its effective date, or March 14, 2015, and is currently in default. Convertible Promissory Note – $97,000 On May 29, 2013, we exchanged $97,000 in demand promissory notes for a 10% convertible promissory note in the aggregate principal amount of $97,000. The note was convertible into shares of our common stock at a price equal to a conversion price of the lesser of $0.28 per share or fifty percent (50%) of the lowest trade price recorded after the effective date. The maturity date of the note was extended to June 30, 2016. We recorded a debt discount of $97,000 related to the beneficial conversion feature of the note, which has been fully amortized to interest expense. The principal balance of $97,000 and accrued interest payable of $27,461 were converted into shares of Series B preferred stock on March 3, 2016. Convertible Promissory Note – Services of $25,000 On June 4, 2013, we entered into a 5% convertible promissory note with a former member of our Board of Directors in exchange for services rendered in the amount of $25,000. The note is convertible into shares of common stock of the Company at a conversion price equal to the lesser of $0.35 per share or the closing price per share of common stock recorded on the trading day immediately preceding the date of conversion. We have entered into an agreement to repay this note with 12 equal monthly payments of principal and interest of $2,352 beginning in June 2016. The note had a principal balance of $10,417 and accrued interest payable of $1,328 at December 31, 2016. Convertible Promissory Note – $5,000 Exchanged Note On September 6, 2013, we exchanged a $5,000 promissory note for a 10% convertible promissory note in the aggregate principal amount of $5,000. The note is convertible into shares of our common stock at a price equal to a conversion price of the lesser of $0.042 per share or fifty percent (50%) of the lowest trade price recorded after the effective date. The note was converted in full to shares of our common stock in February 2017 (Note 13). We recorded a debt discount of $2,536, which has been fully amortized to interest expense, along with a derivative liability at inception. Convertible Promissory Note – $250,000 On October 8, 2012, we entered into to a 10% convertible promissory note in the aggregate principal amount of $250,000. The note is convertible into shares of common stock of the Company at a price equal to the lesser of $0.06 or 50% of the lowest trade price subsequent to the effective date of the note and prior to the conversion. The maturity date of this note was extended to June 30, 2016. The lender previously advanced a total of $11,000 in August and September 2013 that was transferred to this promissory note. We recorded a debt discount of $11,000, which has been fully amortized to interest expense, along with a derivative liability upon transfer. On October 21, 2013, we received additional proceeds of $22,000 on this promissory note. We recorded a debt discount of $22,000, which has been fully amortized to interest expense, along with a derivative liability at inception. On November 22, 2013, we received additional proceeds of $25,000 on this promissory note agreement. We recorded a debt discount of $25,000, which has been fully amortized to interest expense, along with a derivative liability at inception. The total principal balance of $58,000 and total accrued interest payable of $13,609 were converted into shares of Series B preferred stock on March 3, 2016. April 2014 Convertible Promissory Note – $500,000 On April 18, 2014, we entered into a 10% convertible promissory note with an aggregate principal amount of $500,000 (the "April 2014 $500,000 CPN"). The advance amounts received were at the lender's discretion. The note was convertible into shares of our common stock at a price per share equal to the lesser of: $0.03; or 50% of the lowest trade price subsequent to the effective date of the note and prior to the conversion; or the lowest effective price per share granted to any person or entity to acquire common stock subsequent to the effective date of the note. The note matured, with respect to each advance, eighteen months from the effective date of each advance. On April 18, 2014, we received proceeds of $60,000 pursuant to the April 2014 $500,000 CPN. We recorded a debt discount of $60,000 related to the conversion feature of the note, along with a derivative liability at inception. During the year ended December 31, 2015, amortization of debt discount was recorded to interest expense in the amount of $31,861 and the debt discount was fully amortized to interest expense. On May 20, 2014, we received proceeds of $45,000 pursuant to the April 2014 $500,000 SPA. We recorded a debt discount of $45,000 related to the conversion feature of the note, along with a derivative liability at inception. During the year ended December 31, 2015, amortization of debt discount was recorded to interest expense in the amount of $26,557 and the debt discount was fully amortized to interest expense. On June 30, 2014, we received proceeds of $200,000 pursuant to the April 2014 $500,000 CPN. We recorded a debt discount of $200,000 related to the conversion feature of the note, along with a derivative liability at inception. During the year ended December 31, 2015, amortization of debt discount was recorded to interest expense in the amount of $132,847 and the debt discount was fully amortized to interest expense. On July 18, 2014, we received proceeds of $25,000 pursuant to the April 2014 $500,000 CPN. We recorded a debt discount of $25,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $820 and $16,621, respectively, and the debt discount was fully amortized to interest expense. On August 6, 2014, we received proceeds of $65,000 pursuant to the April 2014 $500,000 CPN. We recorded a debt discount of $65,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $4,381 and $43,215, respectively, and the debt discount was fully amortized to interest expense. On August 18, 2014, we received proceeds of $25,000 pursuant to the April 2014 $500,000 CPN. We recorded a debt discount of $25,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $2,231 and $16,621, respectively, and the debt discount was fully amortized to interest expense. On September 9, 2014, we received proceeds of $56,000 pursuant to the April 2014 $500,000 CPN. We recorded a debt discount of $56,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $7,064 and $37,367, respectively, and the debt discount was fully amortized to interest expense. On October 8, 2014, we received proceeds of $24,000 pursuant to the April 2014 $500,000 CPN. We recorded a debt discount of $24,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $4,336 and $15,985, respectively, and the debt discount was fully amortized to interest expense. The total principal balance of $500,000 of the April 2014 $500,000 CPN and total accrued interest payable of $82,677 were converted into shares of Series B preferred stock on March 3, 2016. October 2014 Convertible Promissory Note – $500,000 On October 1, 2014, we entered into a 10% convertible promissory note with an aggregate principal amount of $500,000 (the "October 2014 $500,000 CPN"). The advance amounts received were at the lender's discretion. The note was convertible into shares of our common stock at a price per share equal to the lesser of: $0.03; or 50% of the lowest trade price subsequent to the effective date of the note and prior to the conversion; or the lowest effective price per share granted to any person or entity to acquire common stock subsequent to the effective date of the note. The note was to mature, with respect to each advance, eighteen months from the effective date of each advance. On October 1, 2014, we received proceeds of $65,000 pursuant to the October 2014 $500,000 CPN. We recorded a debt discount of $65,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $10,912 and $43,294, respectively, and the debt discount was fully amortized to interest expense. On November 7, 2014, we received proceeds of $30,000 pursuant to the October 2014 $500,000 CPN. We recorded a debt discount of $30,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $7,020 and $20,018, respectively, and the debt discount was fully amortized to interest expense. On December 9, 2014, we received proceeds of $25,000 pursuant to the October 2014 $500,000 CPN. We recorded a debt discount of $25,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $7,345 and $16,651, respectively, and the debt discount was fully amortized to interest expense. On January 14, 2015, we received proceeds of $92,000 pursuant to the October 2014 $500,000 CPN. We recorded a debt discount of $92,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $32,965 and $59,035, respectively, and the debt discount was fully amortized to interest expense. On February 10, 2015, we received proceeds of $30,000 pursuant to the October 2014 $500,000 CPN. We recorded a debt discount of $30,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $12,230 and $17,770, respectively, and the debt discount was fully amortized to interest expense. On March 16, 2015, we received proceeds of $30,000 pursuant to the October 2014 $500,000 CPN. We recorded a debt discount of $30,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $14,182 and $15,818, respectively, and the debt discount was fully amortized to interest expense. On April 17, 2015, we received proceeds of $45,000 pursuant to the October 2014 $500,000 CPN. We recorded a debt discount of $45,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $23,852 and $21,148, respectively, and the debt discount was fully amortized to interest expense. On May 5, 2015, we received proceeds of $65,000 pursuant to the October 2014 $500,000 CPN. We recorded a debt discount of $65,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $36,636 and $28,364, respectively, and the debt discount was fully amortized to interest expense. On May 11, 2015, we received proceeds of $40,000 pursuant to the October 2014 $500,000 CPN. We recorded a debt discount of $40,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $22,982 and $17,018, respectively, and the debt discount was fully amortized to interest expense. On June 22, 2015, we received proceeds of $35,000 pursuant to the October 2014 $500,000 CPN. We recorded a debt discount of $35,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $22,760 and $12,240, respectively, and the debt discount was fully amortized to interest expense. On June 23, 2015, we received proceeds of $20,000 pursuant to the October 2014 $500,000 CPN. We recorded a debt discount of $20,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $13,042 and $6,958, respectively, and the debt discount was fully amortized to interest expense. On July 9, 2015, we received proceeds of $23,000 pursuant to the October 2014 $500,000 CPN. We recorded a debt discount of $23,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $15,682 and $7,318, respectively, and the debt discount was fully amortized to interest expense. The total principal balance of $500,000 of the October 2014 $500,000 CPN and total accrued interest payable of $50,748 were converted into shares of Series B preferred stock on March 3, 2016. July 2015 Convertible Promissory Note – $500,000 On July 13, 2015, we entered into a 10% convertible promissory note with an aggregate principal amount of $500,000 (the "July 2015 $500,000 CPN"). The advance amounts received were at the lender's discretion. The note was convertible into shares of our common stock at a price per share equal to the lesser of: $0.03; or 50% of the lowest trade price subsequent to the effective date of the note and prior to the conversion; or the lowest effective price per share granted to any person or entity to acquire common stock subsequent to the effective date of the note. The note was to mature, with respect to each advance, eighteen months from the effective date of each advance. On July 13, 2015, we received proceeds of $12,000 pursuant to the July 2015 $500,000 CPN. We recorded a debt discount of $12,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $8,269 and $3,731, respectively, and the debt discount was fully amortized to interest expense. On August 7, 2015, we received proceeds of $65,000 pursuant to the July 2015 $500,000 CPN. We recorded a debt discount of $65,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $47,745 and $17,255, respectively, and the debt discount was fully amortized to interest expense. On September 10, 2015, we received proceeds of $25,000 pursuant to the July 2015 $500,000 CPN. We recorded a debt discount of $25,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $19,881 and $5,119, respectively, and the debt discount was fully amortized to interest expense. On October 13, 2015, we received proceeds of $25,000 pursuant to the July 2015 $500,000 CPN. We recorded a debt discount of $25,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $21,389 and $3,611, respectively, and the debt discount was fully amortized to interest expense. On November 13, 2015, we received proceeds of $25,000 pursuant to the July 2015 $500,000 CPN. We recorded a debt discount of $25,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $22,806 and $2,194, respectively, and the debt discount was fully amortized to interest expense. On December 9, 2015, we received proceeds of $25,000 pursuant to the July 2015 $500,000 CPN. We recorded a debt discount of $25,000 related to the conversion feature of the note, along with a derivative liability at inception. During the years ended December 31, 2016 and 2015, amortization of debt discount was recorded to interest expense in the amount of $23,995 and $1,005, respectively, and the debt discount was fully amortized to interest expense. On January 14, 2016, we received proceeds of $25,000 pursuant to the July 2015 $500,000 CPN. We recorded a debt discount of $25,000 related to the conversion feature of the note, along with a derivative liability at inception. During the year ended December 31, 2016, amortization of debt discount was recorded to interest expense in the amount of $25,000 and the debt discount was fully amortized to interest expense. On February 9, 2016, we received proceeds of $25,000 pursuant to the July 2015 $500,000 CPN. We recorded a debt discount of $25,000 related to the conversion feature of the note, along with a derivative liability at inception. During the year ended December 31, 2016, amortization of debt discount was recorded to interest expense in the amount of $25,000 and the debt discount was fully amortized to interest expense. The total principal balance of $227,000 of the July 2015 $500,000 CPN and total accrued interest payable of $8,498 were converted into shares of Series B preferred stock on March 3, 2016. March 2016 Convertible Promissory Note – $1,000,000 On March 4, 2016, we entered into a convertible promissory note in the aggregate principal amount of $1,000,000 (the "March 2016 $1,000,000 CPN"). The lender may advance the Company consideration in such amounts as the lender may choose in its sole discretion. The note is convertible into shares of our common stock at a price per share equal to the lesser of: $0.03; 50% of the lowest trade price of our common stock subsequent to the effective date of the note; or the lowest effective price per share granted to any person or entity (exclusive of our officers and directors) to acquire common stock subsequent to the effective date of the note. The note initially matured, with respect to each advance, one year from the effective date of each advance. Subsequently, the Lender extended the maturity date, with the note payable upon demand, but in no event later than 60 months from March 4, 2016. On March 4, 2016, we received proceeds of $25,000 pursuant to the March 4, 2016 $1,000,000 CPN. We recorded a debt discount of $25,000 related to the conversion feature of the note, along with a derivative liability at inception. During the year ended December 31, 2016, amortization of debt discount was recorded to interest expense in the amount of $20,685, resulting in a remaining discount of $4,315 at December 31, 2016. On March 14, 2016, we received proceeds of $27,000 pursuant to the March 4, 2016 $1,000,000 CPN. We recorded a debt discount of $27,000 related to the conversion feature of the note, along with a derivative liability at inception. During the year ended December 31, 2016, amortization of debt discount was recorded to interest expense in the amount of $21,600, resulting in a remaining discount of $5,400 at December 31, 2016. On March 17, 2016, we received proceeds of $33,000 pursuant to the March 4, 2016 $1,000,000 CPN. We recorded a debt discount of $33,000 related to the conversion feature of the note, along with a derivative liability at inception. During the year ended December 31, 2016, amortization of debt discount was recorded to interest expense in the amount of $21,608, resulting in a remaining discount of $11,392 at December 31, 2016. On April 11, 2016, we received proceeds of $90,000 pursuant to the March 4, 2016 $1,000,000 CPN. We recorded a debt discount of $90,000 related to the conversion feature of the note, along with a derivative liability at inception. During the year ended December 31, 2016, amortization of debt discount was recorded to interest expense in the amount of $65,096, resulting in a remaining discount of $24,904 at December 31, 2016. On May 20, 2016, we received proceeds of $60,000 pursuant to the March 4, 2016 $1,000,000 CPN. We recorded a debt discount of $60,000 related to the conversion feature of the note, along with a derivative liability at inception. During the year ended December 31, 2016, amortization of debt discount was recorded to interest expense in the amount of $36,986, resulting in a remaining discount of $23,014 at December 31, 2016. On June 22, 2016, we received proceeds of $50,000 pursuant to the March 4, 2016 $1,000,000 CPN. We recorded a debt discount of $50,000 related to the conversion feature of the note, along with a derivative liability at inception. During the year ended December 31, 2016, amortization of debt discount was recorded to interest expense in the amount of $36,301, resulting in a remaining discount of $23,699 at December 31, 2016. On July 6, 2016, we received proceeds of $87,000 pursuant to the March 4, 2016 $1,000,000 CPN. We recorded a debt discount of $87,000 related to the conversion feature of the note, along with a derivative liability at inception. During the year ended December 31, 2016, amortization of debt discount was recorded to interest expense in the amount of $42,427, resulting in a remaining discount of $44,573 at December 31, 2016. On August 8, 2016, we received proceeds of $60,000 pursuant to the March 4, 2016 $1,000,000 CPN. We recorded a debt discount of $60,000 related to the conversion feature of the note, along with a derivative liability at inception. During the year ended December 31, 2016, amortization of debt discount was recorded to interest expense in the amount of $23,836, resulting in a remaining discount of $36,164 at December 31, 2016. On September 13, 2016, we received proceeds of $55,000 pursuant to the March 4, 2016 $1,000,000 CPN. We recorded a debt discount of $55,000 related to the conversion feature of the note, along with a derivative liability at inception. During the year ended December 31, 2016, amortization of debt discount was recorded to interest expense in the amount of $16,425, resulting in a remaining discount of $38,575 at December 31, 2016. On October 17, 2016, we received proceeds of $55,000 pursuant to the March 4, 2016 $1,000,000 CPN. We recorded a debt discount of $55,000 related to the conversion feature of the note, along with a derivative liability at inception. During the year ended December 31, 2016, amortization of debt discount was recorded to interest expense in the amount of $11,301, resulting in a remaining discount of $43,699 at December 31, 2016. On November 8, 2016, we received proceeds of $55,000 pursuant to the March 4, 2016 $1,000,000 CPN. We recorded a debt discount of $55,000 related to the conversion feature of the note, along with a derivative liability at inception. During the year ended December 31, 2016, amortization of debt discount was recorded to interest expense in the amount of $7,986, resulting in a remaining discount of $47,014 at December 31, 2016. On December 6, 2016, we received proceeds of $60,000 pursuant to the March 4, 2016 $1,000,000 CPN. We recorded a debt discount of $60,000 related to the conversion feature of the note, along with a derivative liability at inception. During the year ended December 31, 2016, amortization of debt discount was recorded to interest expense in the amount of $3,767, resulting in a remaining discount of $56,233 at December 31, 2016. The total loss on settlement of debt, including conversions of notes payable, was $33,561 for the year ended December 31, 2016. The total gain on settlement of debt was $5,660 for the year ended December 31, 2015.

6. Derivative Liabilities

6. Derivative Liabilities	12 Months Ended
	Dec. 31, 2016
Notes
6. Derivative Liabilities	6. DERIVATIVE LIABILITIES The fair value of the Company's derivative liabilities is estimated at the issuance date and is revalued at each subsequent reporting date. For purpose of estimating the fair value of the derivative liabilities associated with our convertible notes payable, we used the Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuation of the derivative liabilities at December 31, 2016 and 2015 are as follows: 2016 2015 Stock price on the valuation date $0.0254 $0.004 Conversion price for the debt $0.0763 - $0.0045 $0.004 - $0.0045 Dividend yield 0.00% 0.00 Years to maturity .20 - 1.00 1.00 - 1.44 Risk free rate .51% - .85% .65-.86% Expected volatility 115.06% - 189.59% 103.67-151.10% The value of the derivative liabilities associated with our convertible notes payable at December 31, 2016 and December 31, 2015 was estimated at $3,335,906 and $13,184,369, respectively. These inputs are subject to significant changes and market fluctuations from period to period; therefore, the estimated fair value of the derivative liability will fluctuate from period to period and the fluctuation may be material. For purpose of estimating the fair value of the derivative liability associated with our Series B preferred stock, we used a multinomial lattice model based on projections of various potential future outcomes. The significant assumptions used in the valuation of the derivative liability at December 31, 2016 are as follows: Conversion to stock Monthly Stock price on the valuation date $0.0254 Conversion price $0.0045 Years to maturity 15.0 Expected volatility 245.3% The value of the derivative liability associated with our Series B convertible preferred stock at December 31, 2016 was estimated at $3,354,791. These inputs are subject to significant changes from period to period and to management's judgment; therefore, the estimated fair value of the derivative liability will fluctuate from period to period, and the fluctuation may be material.

7. Research Agreements and Form

7. Research Agreements and Formation of subsidiary	12 Months Ended
	Dec. 31, 2016
Notes
7. Research Agreements and Formation of subsidiary	7. RESEARCH AGREEMENTS AND FORMATION OF SUBSIDIARY On June 18, 2014, we entered into a Sponsored Research Agreement ("SRA #1") with UCSB, pursuant to which UCSB performed research work for the mutual benefit of UCSB and the Company. The purpose of SRA #1 included the development of a low-cost and scalable method to produce large-area graphene for transparent electrode applications. The term of SRA #1 commenced on July 1, 2014 and expired on June 30, 2015. The total cost to the Company was $387,730, which has been fully paid. The Company amortized the SRA #1 payments over the life of the contract. Research and development expenses for the year ended December 31, 2015 included $193,865 related to the SRA #1. On December 15, 2015, we entered into a second Sponsored Research Agreement ("SRA #2") with UCSB, pursuant to which UCSB will perform research work for the mutual benefit of UCSB and the Company. The purpose of SRA #2 includes the development of a graphene based optical modulator for the high-speed transmission of digital data in fiber optic networks. The term of SRA #2 commenced on January 1, 2016 and expired on June 30, 2016. The total cost to the Company was $65,497, which is reported as research and development expenses for the year ended December 31, 2016. Subsequent to December 31, 2016, we entered into our third SRA with UCSB to further develop a graphene-based device (see Note 13). On January 5, 2015, the Company formed Transphene, Inc., a Nevada corporation ("Transphene"), of which the Company owns 50% of the total issued and outstanding capital stock. The remaining 50% is owned by Dr. Kaustav Banerjee ("Banerjee"), a director and Chief Technical Officer of Transphene. Transphene is formed to commercialize any technology that the Company licenses out of SRA #1. In consideration for its interest in Transphene, the Company assigned to Transphene the intellectual property rights acquired by the Company from SRA #1. The Company and Banerjee also entered into a Shareholders' Agreement pursuant to which the Company and Banerjee agreed to (i) vote their shares to elect Mr. William E. Beifuss, Jr., President and Chief Executive Officer of the Company, and Banerjee as the directors of Transphene and (ii) not sell or transfer shares until the selling shareholder first offers its shares to the other shareholder. At this time, the Company does not see an opportunity to commercialize the research findings of SRA #1, has not licensed any intellectual property from UCSB, and therefore has not assigned any intellectual property to Transphene. Therefore, we terminated our joint venture through Transphene and wound up and dissolved Transphene in 2016. There have been no financial transactions in Transphene and no impact on our financial statements.

8. Supplemental Statement of Ca

8. Supplemental Statement of Cash Flows Information	12 Months Ended
	Dec. 31, 2016
Notes
8. Supplemental Statement of Cash Flows Information	8. SUPPLEMENTAL STATEMENT OF CASH FLOWS INFORMATION During the years ended December 31, 2016 and 2015, we paid no amounts for income taxes. During the years ended December 31, 2016 and 2015, we paid cash for interest expense of $1,860 and $0, respectively. During the year ended December 31, 2016, the Company had the following non-cash investing and financing activities: The Company issued a total of 3,028,018 shares of common stock for the conversion of $10,450 in convertible notes payable, plus $3,17 of accrued interest payable, increasing common stock by $3,028, increasing additional paid-in capital by $83,359, decreasing derivative liabilities by $33,756 and recording a loss on settlement of debt of $39,005. The Company increased debt discount and derivative liabilities by $707,000 for the issuance of new convertible debt. The Company issued a total of 16,155 shares of Series B preferred stock for the conversion of $1,615,362 in convertible notes payable, plus $264,530 of accrued interest payable, increasing Series B preferred stock by $1, increasing additional paid-in capital by $11,630,806 and decreasing derivative liabilities by $9,750,930. The Company increased derivative liabilities and decreased additional paid-in capital by $3,908,211 for derivative liabilities associated with the issuance of Series B preferred stock. The Company increased common stock and decreased additional paid-in capital by $1 for the par value of additional shares of common stock issued in the reverse stock split. The Company decreased convertible notes payable by $185,752, accrued interest payable by $33,199 and derivative liabilities by $106,858 and increased additional paid-in capital by $325,80 for settlement of related party debt recorded as a contribution to capital. During the year ended December 31, 2015, the Company had the following non-cash investing and financing activities: The Company issued a total of 80,311,720 shares of common stock for the conversion of $29,200 in convertible notes payable, plus $6,940 of accrued interest payable, increasing common stock by $80,313, increasing additional paid-in capital by $642,074, decreasing derivative liability by $691,907 and recording a gain on settlement of debt of $5,660. The Company increased debt discount and derivative liability by $557,000 for the issuance of new convertible debt.

9. Income Taxes

9. Income Taxes	12 Months Ended
	Dec. 31, 2016
Notes
9. Income Taxes	9. INCOME TAXES A reconciliation of the income tax provision (benefit) that would result from applying a combined U.S. federal and state rate of 43% to loss before income taxes with the provision (benefit) for income taxes presented in the financial statements is as follows: Years Ended December 31, 2016 2015 Income tax benefit at statutory rate $(119,400) $(2,243,800) State income taxes, net of federal benefit (300) (300) Nondeductible stock deductions 61,900 1,928,300 Other (12,200) - Valuation allowance 70,000 315,800 ~ ~ Deferred tax assets (liabilities) are comprised of the following: December 31, 2016 2015 Deferred tax assets: Net operating loss carryforward $3,839,800 $3,782,600 Research and development credit carryforward 125,200 100,100 Related party accrued expenses 600 13,400 Accrued compensated absences 900 400 Valuation allowance (3,966,500) (3,896,500) $- $- The ultimate realization of our deferred tax assets is dependent, in part, upon the tax laws in effect, our future earnings, and other events. As of December 31, 2016, we recorded a valuation allowance of $3,966,500 against net current deferred tax. In recording the valuation allowance, we were unable to conclude that it is more likely than not that our deferred tax assets will be realized. As of December 31, 2016, we had a net operating loss carryforward available to offset future taxable income of approximately $8,930,000, which begins to expire at dates that have not been determined. If substantial changes in the Company's ownership should occur, there would be an annual limitation of the amount of the net operating loss carryforward that could be utilized. We perform a review of our material tax positions in accordance with recognition and measurement standards established by authoritative accounting literature, which requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. Based upon our review and evaluation, during the years ended December 31, 2016 and 2015, we concluded the Company had no unrecognized tax benefit that would affect its effective tax rate if recognized. We file income tax returns in the U.S. federal jurisdiction and in the state of California. With few exceptions, we are no longer subject to U.S. federal, state or local income tax examinations by tax authorities for years before 2011. We classify any interest and penalties arising from the underpayment of income taxes in our statements of operations and comprehensive loss in other income (expense). As of December 31, 2016 and 2015, we had no accrued interest or penalties related to uncertain tax positions.

10. Related Party Transactions

10. Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Notes
10. Related Party Transactions	10. RELATED PARTY TRANSACTIONS See Note 3 for a discussion regarding the issuance of 1,000 shares of Series A Preferred Stock to the Company's President and director, William E. Beifuss, Jr., for services rendered. The shares were subsequently automatically redeemed on the date 90 days after the effective date of the Series A Certificate. See Note 5 for discussion of convertible notes payable with related parties, including multiple lenders who are also shareholders of the Company. On December 12, 2012, we entered into a 5% convertible note with the Chairman of our Board of Directors and our former Chief Executive Officer in exchange for services valued at $185,852. The principal balance of this related party note was $185,852 as of December 31, 2015 and 2014, with accrued interest payable of $27,878 and $18,585 as of December 31, 2015 and 2014, respectively. The note was to mature on December 31, 2016. On July 27, 2016, we entered into a Settlement and Release Agreement with the Chairman for full extinguishment of the above described convertible promissory note with a principal balance of $185,852, plus accrued interest. We agreed to pay the Chairman $100 in cash and arranged for him to enter into an option agreement with our principal lender and a principal holder of our Series B preferred stock ("Lender") to acquire 225 shares of our Series B preferred stock from the Lender upon the occurrence of certain events defined in the agreement. Due to the related party nature of this transaction, the extinguishments of the note principal of $185,752, accrued interest payable of $33,199 and associated derivative liability of $106,858 were recorded to additional paid-in capital as a contribution to capital totaling $325,809. On June 4, 2013, we entered into a convertible note with a former member of our Board of Directors in exchange for services valued at $25,000. As of December 31, 2015 and 2014, the principal balance of this related party note was $25,000, with accrued interest payable of $3,219 and $1,969 as of December 31, 2015 and 2014, respectively. The note was to mature on June 4, 2016. We have entered into an agreement to repay this note in 12 equal monthly payments of principal and interest of $2,352, beginning in June 2016. The note had a principal balance of $10,417 and accrued interest payable of $1,328 at December 31, 2016.

11. Commitments and Contingenci

11. Commitments and Contingencies - Operating Lease	12 Months Ended
	Dec. 31, 2016
Notes
11. Commitments and Contingencies - Operating Lease	11. COMMITMENTS AND CONTINGENCIES - OPERATING LEASE We extended our facility lease for a period of five years, expiring on September 30, 2017. The base rent for the period of October 1, 2012 to September 30, 2013 was $2,884 per month, for the period October 1, 2014 to September 30, 2015 was $3,450 per month , for the period October 1, 2015 to September 30, 2016 was $3,533 per month

12. Consulting Agreements

12. Consulting Agreements	12 Months Ended
	Dec. 31, 2016
Notes
12. Consulting Agreements	12. CONSULTING AGREEMENT We have a written consulting agreement dated May 31, 2013 with William E. Beifuss, Jr., our President, Acting Chief Financial Officer, and former Chief Executive Officer for the payment of monthly compensation of $5,000 per month beginning in June 2013. The agreement may be cancelled by either party with 30 days' notice.

13. Subsequent Events

13. Subsequent Events	12 Months Ended
	Dec. 31, 2016
Notes
13. Subsequent Events	13. SUBSEQUENT EVENTS Management has evaluated subsequent events according to the requirements of ASC TOPIC 855, and has reported the following: Debt Conversion Subsequent to December 31, 2016, we issued a lender 1,496,499 shares of our common stock for the conversion of debt in the principal amount of $5,000 and accrued interest of $1,734. Subsequent Borrowings We received proceeds of $60,000 in each of January and February 2017 from the March 2016 $1,000,000 CPN. Extension of Maturity Dates of Convertible Promissory Notes Subsequent to December 31, 2016, the maturity dates of certain convertible promissory notes were extended to various dates in 2017. See Note 5.

2. Summary of Significant Acc20

2. Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Policies
Revenue Recognition	Revenue Recognition We will recognize revenue when services are performed, and at the time of shipment of products, provided that evidence of an arrangement exists, title and risk of loss have passed to the customer, fees are fixed or determinable, and collection of the related receivable is reasonably assured. To date, we have had no revenues.
Cash and Cash Equivalent	Cash and Cash Equivalents We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements include the estimate of useful lives of property and equipment, the deferred tax valuation allowance, the fair value of stock options and derivative liabilities. Actual results could differ from those estimates.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, and are depreciated using the straight line method over the following estimated useful lives: Computer equipment 3 Years Machinery and equipment 7 Years Depreciation expense for the years ended December 31, 2016 and 2015 was $617 and $208, respectively.
Derivative Liability	Derivative Liabilities We have identified the conversion features of our convertible notes payable and our Series B preferred stock as derivatives. We estimate the fair value of the derivatives associated with our convertible notes payable using the Black-Scholes pricing model and estimate the fair value of the derivatives associated with our Series B preferred stock using a multinomial lattice model based on projections of various potential future outcomes. We estimate the fair value of the derivative liabilities at the inception of the financial instruments, at the date of conversions to equity and at each reporting date, recording a derivative liability, debt discount, additional paid-in capital and a gain or loss on change in derivative liabilities as applicable. These estimates are based on multiple inputs, including the market price of our stock, interest rates, our stock price volatility, variable conversion prices based on market prices as defined in the respective agreements and probabilities of certain outcomes based on management projections. These inputs are subject to significant changes from period to period and to management's judgment; therefore, the estimated fair value of the derivative liabilities will fluctuate from period to period, and the fluctuation may be material.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Disclosures about fair value of financial instruments require disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of December 31, 2016 and 2015, the amounts reported for cash, accrued interest, accrued expenses and other current liabilities, and notes payable approximate fair value because of their short maturities. We adopted ASC Topic 820 (originally issued as SFAS 157, "Fair Value Measurements") as of January 1, 2008 for financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States, and expands disclosures about fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include: · Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; · Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and · Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows at December 31, 2016 and 2015: Total Level 1 Level 2 Level 3 December 31, 2016: Derivative liabilities $6,690,697 $ - $ - $6,690,697 Total liabilities measured at fair value $6,690,697 $ - $ - $6,690,697 December 31, 2015: Derivative liabilities $13,184,369 $ - $ - $ 13,184,369 Total liabilities measured at fair value $13,184,369 $ - $ - $13,184,369 During the years ended December 31, 2016 and 2015, the Company had the following activity in its derivative liabilities account: Convertible Notes Series B Payable Preferred Stock Total Derivative liabilities at December 31, 2014 $9,476,605 $ - $9,476,605 Addition to liability for new debt issued 557,000 - 557,000 Elimination of liability on conversion (691,907) - (691,907) Change in fair value 3,842,671 - 3,842,671 Derivative liabilities at December 31, 2015 13,184,369 - 13,184,369 Addition to liability for new debt/shares issued 707,000 3,908,211 4,615,211 Elimination of liability on conversion to common shares (33,756) - (33,756) Elimination of liability on conversion to preferred shares (9,750,930) - (9,750,930) Contribution of liability to capital on settlement of related party debt (106,858) - (106,858) Change in fair value (663,919) (553,420) (1,217,339) Derivative liabilities at December 31, 2016 $3,335,906 $3,354,791 $6,690,697
Loss Per Share Calculations	Loss per Share Calculations Basic net income or loss per common share is computed by dividing net income or loss by the weighted average number of common shares outstanding. Diluted net income or loss per common share is computed by dividing net income or loss by the sum of the weighted average number of common shares outstanding and the dilutive potential common share equivalents then outstanding. Potential dilutive common share equivalents consist of shares issuable upon the exercise of outstanding stock options and warrants to acquire common stock using the treasury stock method and the average market price per share during the period, and shares issuable upon exercise of convertible notes payable and convertible preferred stock. Since we had no dilutive effect of stock options and warrants for the years ended December 31, 2016 and 2015, our basic weighted average number of common shares outstanding is the same as our diluted weighted average number of common shares outstanding. For the year ended December 31, 2016, the Company has excluded 1,410,000 common shares for exercisable options, 46,000 common shares for exercisable warrants, approximately 157,269,000 shares issuable upon conversion of convertible notes payable and approximately 367,000,000 common shares upon conversion of convertible Series B preferred stock. For the year ended December 31, 2015, the Company has excluded 1,410,000 common shares for exercisable options, 46,000 common shares for exercisable warrants and approximately 3,738,502,000 shares issuable upon conversion of convertible notes payable.
Income Taxes	Income Taxes We account for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
Research and Development	Research and Development Research and development costs are expensed as incurred. Total research and development costs were $65,497 and $298,865 for the years ended December 31, 2016 and 2015, respectively.
Advertising Costs	Advertising Costs We expense the cost of advertising and promotional materials when incurred. We incurred no advertising costs for the years ended December 31, 2016 and 2015.
Stock-based Compensation	Stock-Based Compensation Stock-based compensation is measured at the grant date based on the value of the award granted using the Black-Scholes option pricing model, and recognized over the period in which the award vests. For stock awards no longer expected to vest, any previously recognized stock compensation expense is reversed in the period of termination. The stock-based compensation expense is included in general and administrative expenses.
Comprehensive Loss	Comprehensive Loss Comprehensive loss is the same as net loss for all years presented.
Reclassifications	Reclassifications Certain amounts in the prior years have been reclassified to conform to the current year presentation.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In January 2017, the FASB issued Accounting Standards Update ("ASU") No. 2017-4, "Intangibles – Goodwill and Other (Topic 350): "Simplifying the Test for Goodwill Impairment." This update simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit's goodwill with the carrying amount of that goodwill. Instead, under the amendments in this update, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. An entity should apply the amendments in this update on a prospective basis. An entity is required to disclose the nature of and reason for the change in accounting principle upon transition. That disclosure should be provided in the first annual period and in the interim period within the first annual period when the entity initially adopts the amendments in this update. A public business entity that is an SEC filer should adopt the amendments in this Update for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company is currently unable to determine the impact on its financial statements of the adoption of this new accounting pronouncement. In January 2017, the FASB issued ASU No. 2017-1, "Business Combinations (Topic 805): Clarifying the Definition of a Business." The amendments in this update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The amendments of this ASU are effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019. The amendments in this Update are to be applied prospectively on or after the effective date. The Company is currently unable to determine the impact on its financial statements of the adoption of this new accounting pronouncement. In October 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-17, "Consolidation (Topic 810): Interests Held Through Related Parties That are Under Common Control." This update amends the consolidation guidance on how a reporting entity that is the single decision maker of a variable interest entity ("VIE") should treat indirect interests in the entity held through related parties that are under common control with the reporting entity when determining whether it is the primary beneficiary of that VIE. The primary beneficiary of a VIE is the reporting entity that has a controlling financial interest in a VIE and, therefore, consolidates the VIE. A reporting entity has an indirect interest in a VIE if it has a direct interest in a related party that, in turn, has a direct interest in the VIE. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently unable to determine the impact on its financial statements of the adoption of this new accounting pronouncement. In August 2016, the FASB issued ASU No. 2016-15, "Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments." This ASU addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently unable to determine the impact on its financial statements of the adoption of this new accounting pronouncement. Although there are several other new accounting pronouncements issued or proposed by the FASB, which the Company has adopted or will adopt, as applicable, the Company does not believe any of these accounting pronouncements has had or will have a material impact on its financial position or results of operations.

2. Summary of Significant Acc21

2. Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Tables/Schedules
Schedule of Balances of Derivatives	We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows at December 31, 2016 and 2015: Total Level 1 Level 2 Level 3 December 31, 2016: Derivative liabilities $6,690,697 $ - $ - $6,690,697 Total liabilities measured at fair value $6,690,697 $ - $ - $6,690,697 December 31, 2015: Derivative liabilities $13,184,369 $ - $ - $ 13,184,369 Total liabilities measured at fair value $13,184,369 $ - $ - $13,184,369
Schedule of Activities of Derivatives	During the years ended December 31, 2016 and 2015, the Company had the following activity in its derivative liabilities account: Convertible Notes Series B Payable Preferred Stock Total Derivative liabilities at December 31, 2014 $9,476,605 $ - $9,476,605 Addition to liability for new debt issued 557,000 - 557,000 Elimination of liability on conversion (691,907) - (691,907) Change in fair value 3,842,671 - 3,842,671 Derivative liabilities at December 31, 2015 13,184,369 - 13,184,369 Addition to liability for new debt/shares issued 707,000 3,908,211 4,615,211 Elimination of liability on conversion to common shares (33,756) - (33,756) Elimination of liability on conversion to preferred shares (9,750,930) - (9,750,930) Contribution of liability to capital on settlement of related party debt (106,858) - (106,858) Change in fair value (663,919) (553,420) (1,217,339) Derivative liabilities at December 31, 2016 $3,335,906 $3,354,791 $6,690,697

3. Capital Stock (Tables)

3. Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2016
Tables/Schedules
Schedule of Conversions of Convertible Notes Payable	At the date of conversion, the Prior Notes and accrued interest payable consisted of the following: Effective Date Principal Accrued Interest December 12, 2012 $198,912 $71,929 February 22, 2013 34,450 9,607 May 29, 2013 97,000 27,461 October 7, 2013 58,000 13,609 April 18, 2014 500,000 82,677 October 1, 2014 500,000 50,749 July 13, 2015 227,000 8,498 Total $1,615,362 $264,530

4. Stock Options, Warrants an23

4. Stock Options, Warrants and Restricted Stock Awards (Tables)	12 Months Ended
	Dec. 31, 2016
Tables/Schedules
Schedule of Stock Options, Activity	A summary of the Company's stock option awards as of December 31, 2016, and changes during the year then ended is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contract Term (Years) Aggregate Intrinsic Value Outstanding at December 31, 2015 1,410,000 $0.19 Granted - $- Exercised - $- Forfeited or expired - $- Outstanding and exercisable at December 31, 2016 1,410,000 $0.19 3.72 $-

6. Derivative Liabilities (Tabl

6. Derivative Liabilities (Tables)	12 Months Ended
	Dec. 31, 2016
Series B Preferred Stock
Fair Value Inputs, Quantitative Information	The significant assumptions used in the valuation of the derivative liability at December 31, 2016 are as follows: Conversion to stock Monthly Stock price on the valuation date $0.0254 Conversion price $0.0045 Years to maturity 15.0 Expected volatility 245.3%
Convertible Notes, Current
Fair Value Inputs, Quantitative Information	The significant assumptions used in the Black Scholes valuation of the derivative liabilities at December 31, 2016 and 2015 are as follows: 2016 2015 Stock price on the valuation date $0.0254 $0.004 Conversion price for the debt $0.0763 - $0.0045 $0.004 - $0.0045 Dividend yield 0.00% 0.00 Years to maturity .20 - 1.00 1.00 - 1.44 Risk free rate .51% - .85% .65-.86% Expected volatility 115.06% - 189.59% 103.67-151.10%

9. Income Taxes (Tables)

9. Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Tables/Schedules
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the income tax provision (benefit) that would result from applying a combined U.S. federal and state rate of 43% to loss before income taxes with the provision (benefit) for income taxes presented in the financial statements is as follows: Years Ended December 31, 2016 2015 Income tax benefit at statutory rate $(119,400) $(2,243,800) State income taxes, net of federal benefit (300) (300) Nondeductible stock deductions 61,900 1,928,300 Other (12,200) - Valuation allowance 70,000 315,800 ~ ~
Schedule of Deferred Tax Assets and Liabilities	Deferred tax assets (liabilities) are comprised of the following: December 31, 2016 2015 Deferred tax assets: Net operating loss carryforward $3,839,800 $3,782,600 Research and development credit carryforward 125,200 100,100 Related party accrued expenses 600 13,400 Accrued compensated absences 900 400 Valuation allowance (3,966,500) (3,896,500) $- $-

1. Organization and Line of B26

1. Organization and Line of Business (Details)	Jan. 31, 2015
Transphene, Inc.
Noncontrolling Interest, Ownership Percentage by Parent	50.00%

2. Summary of Significant Acc27

2. Summary of Significant Accounting Policies: Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Depreciation and amortization	$ 617	$ 208
Computer Equipment
Property, Plant and Equipment, Useful Life	3 years
Machinery and Equipment
Property, Plant and Equipment, Useful Life	7 years

2. Summary of Significant Acc28

2. Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Schedule of Balances of Derivatives (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Liabilities, Fair Value Disclosure, Recurring	$ 6,690,697	$ 13,184,369
Fair Value, Inputs, Level 1
Liabilities, Fair Value Disclosure, Recurring	0	0
Fair Value, Inputs, Level 2
Liabilities, Fair Value Disclosure, Recurring	0	0
Fair Value, Inputs, Level 3
Liabilities, Fair Value Disclosure, Recurring	6,690,697	13,184,369
Derivative Financial Instruments, Liabilities
Liabilities, Fair Value Disclosure, Recurring	6,690,697	13,184,369
Derivative Financial Instruments, Liabilities | Fair Value, Inputs, Level 1
Liabilities, Fair Value Disclosure, Recurring	0	0
Derivative Financial Instruments, Liabilities | Fair Value, Inputs, Level 2
Liabilities, Fair Value Disclosure, Recurring	0	0
Derivative Financial Instruments, Liabilities | Fair Value, Inputs, Level 3
Liabilities, Fair Value Disclosure, Recurring	$ 6,690,697	$ 13,184,369

2. Summary of Significant Acc29

2. Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Schedule of Activities of Derivatives (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	$ 6,690,697	$ 13,184,369	$ 9,476,605
Addition to liability for new debt/shares issued	4,615,211	557,000
Elimination of liability on conversion	(691,907)
Change in fair value	(1,217,339)	3,842,671
Elimination of liability on conversion to common shares	(33,756)
Elimination of liability on conversion to preferred shares	(9,750,930)
Conversion to capital of related party debt	(106,858)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Ending Balance	6,690,697	13,184,369
Series B Preferred Stock
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value		0	0
Addition to liability for new debt/shares issued	3,908,211	0
Elimination of liability on conversion	0
Change in fair value	(553,420)	0
Elimination of liability on conversion to common shares	0
Elimination of liability on conversion to preferred shares	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Ending Balance		0
Convertible Notes, Current
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	3,335,906	13,184,369	$ 9,476,605
Addition to liability for new debt/shares issued	707,000	557,000
Elimination of liability on conversion	(691,907)
Change in fair value	(663,919)	3,842,671
Elimination of liability on conversion to common shares	(33,756)
Elimination of liability on conversion to preferred shares	(9,750,930)
Conversion to capital of related party debt	(106,858)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Ending Balance	$ 3,335,906	$ 13,184,369

2. Summary of Significant Acc30

2. Summary of Significant Accounting Policies: Loss Per Share Calculations (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Potentially Dilutive Shares	0	0
Series B Preferred Stock
Antidilituve Securities Excluded from Computation of EPS	367,000,000
Stock Options
Antidilituve Securities Excluded from Computation of EPS	1,410,000	1,410,000
Warrant
Antidilituve Securities Excluded from Computation of EPS	46,000	46,000
Convertible Promissory Notes
Antidilituve Securities Excluded from Computation of EPS	157,269,000	3,738,502,000

2. Summary of Significant Acc31

2. Summary of Significant Accounting Policies: Research and Development (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Details
Research and development	$ 65,497	$ 298,865

3. Capital Stock (Details)

3. Capital Stock (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016		Dec. 31, 2015		Apr. 30, 2016	Mar. 02, 2016
Common Stock, shares authorized	2,000,000,000		2,000,000,000		2,000,000,000
Common Stock Par Value	$ 0.001		$ 0.001
Preferred Stock, shares authorized	20,000,000		20,000,000
Preferred Stock, par or stated value	$ 0.001		$ 0.001
Issuance of common stock for conversion of notes payable and accrued interest payable, Value	$ 86,387		$ 722,387
Increase (Decrease) in Derivative Liabilities	(33,756)		(691,907)
Adjustments to Additional Paid in Capital	$ 11,630,806
Voting power for the merger	50.00%
Reverse stock split	On April 20, 2016, the Company amended its articles of incorporation to reduce the number of authorized shares of common stock from 1,000,000,000 to 100,000,000 and to affect a one-for-ten reverse stock split of its authorized, issued and outstanding shares of common stock.
(Loss) gain on settlement of debt	$ (33,561)		5,660
(Loss) gain on settlement of debt	(33,561)		5,660
Convertible Notes, Non-Current
Adjustments to Additional Paid in Capital			642,074
(Loss) gain on settlement of debt	(39,005)
(Loss) gain on settlement of debt	(39,005)
Principal
Debt Conversion, Original Debt, Amount	10,450		29,200
(Loss) gain on settlement of debt			5,660
(Loss) gain on settlement of debt			5,660
Accrued Interest
Debt Conversion, Original Debt, Amount	3,176		6,940
Derivative Liability
Debt Conversion, Original Debt, Amount			$ 691,907
Prior Notes
Convertible Notes Payable	$ 1,615,362
Debt Instrument, Interest Rate During Period	10.00%
Chief Executive Officer
Increase (Decrease) in Derivative Liabilities	$ (106,858)
Series B Preferred Stock
Issuance of common stock for conversion of notes payable and accrued interest payable, Value	1
Increase (Decrease) in Derivative Liabilities	(9,750,930)
Preferred Stock
Increase (Decrease) in Derivative Liabilities	$ 3,908,211
Preferred Stock | Series A Preferred Stock
Preferred Stock, par or stated value	$ 0.001
Super majority voting power	51.00%
Affirmative vote percentage	66.67%
Preferred Stock | Series A Preferred Stock | Chief Executive Officer
Issuance of Series B preferred shares for conversion, Shares	1,000
Preferred Stock | Series B Preferred Stock
Preferred Stock, shares authorized						30,000
Preferred Stock, par or stated value	$ 100					$ 0.001
Issuance of common stock for conversion of notes payable and accrued interest payable, Shares	16,155
Issuance of common stock for conversion of notes payable and accrued interest payable, Value	$ 1,615,500
Increase (Decrease) in Derivative Liabilities	3,908,211
Adjustments to Additional Paid in Capital	11,630,806
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt	(3,908,211)
Preferred Stock, Including Additional Paid in Capital	$ 3,000,000
Conversion Price Description	The conversion price is the lesser of (1) Fifty Percent (50%) of the lowest trade price of Common Stock recorded on any trade day after December 12, 2012 or (2) the lowest effective price per share granted to any person or entity, including the Holder but excluding officers and directors of the Company, to acquire Common Stock, or adjusted, whether by operation of purchase price adjustment, settlement agreements, exchange agreements, reset provision, floating conversion or otherwise, any outstanding warrant, option or other right to acquire Common Stock or outstanding Common Stock equivalents (the 'Conversion Price').
Debt Conversion, Converted Instrument, Shares Issued	16,155
Debt Conversion, Original Debt, Amount	$ 1,615,362
Preferred Stock | Series B Preferred Stock | Accrued Interest
Debt Conversion, Original Debt, Amount	$ 264,530
Common Stock
Issuance of common stock for conversion of notes payable and accrued interest payable, Shares	3,028,018	[1]	8,031,172	[2]
Issuance of common stock for conversion of notes payable and accrued interest payable, Value	$ 3,028	[1]	$ 8,031	[2]
Debt Conversion, Converted Instrument, Shares Issued	3,028,018		80,311,720
Total Stock Issued During Period			8,031,172
Common Stock | ReverseStockSplitMember
Issuance of common stock for conversion of notes payable and accrued interest payable, Value	$ 1
Debt Conversion, Converted Instrument, Shares Issued	816
Common Stock | Convertible Notes, Non-Current
Issuance of common stock for conversion of notes payable and accrued interest payable, Value			$ 80,313
Adjustments to Additional Paid in Capital	$ 83,359
Additional Paid-in Capital
Issuance of common stock for conversion of notes payable and accrued interest payable, Value	83,359		$ 714,356
Additional Paid-in Capital | ReverseStockSplitMember
Issuance of common stock for conversion of notes payable and accrued interest payable, Value	$ (1)
[1]	3,028,018 shares issued at fair value at $0.028 - $0.029 per share
[2]	8,031,172 shares issued at fair value at $0.055 - $0.135 per share

3. Capital Stock_ Schedule of C

3. Capital Stock: Schedule of Conversions of Convertible Notes Payable (Details) - Prior Notes - USD ($)	Jul. 13, 2015	Oct. 01, 2014	Apr. 18, 2014	Oct. 07, 2013	May 29, 2013	Feb. 22, 2013	Dec. 12, 2012	Dec. 31, 2016
Convertible Notes Payable								$ 1,615,362
Accrued Interest								$ 264,530
Convertible Promissory Note 5
Convertible Notes Payable							$ 198,912
Accrued Interest							$ 71,929
Convertible Promissory Note 7
Convertible Notes Payable						$ 34,450
Accrued Interest						$ 9,607
Convertible Promissory Note 13
Convertible Notes Payable					$ 97,000
Accrued Interest					$ 27,461
Convertible Promissory Note 8
Convertible Notes Payable				$ 58,000
Accrued Interest				$ 13,609
Convertible Promissory Note 18
Convertible Notes Payable			$ 500,000
Accrued Interest			$ 82,677
Convertible Promissory Note 19
Convertible Notes Payable		$ 500,000
Accrued Interest		$ 50,749
Convertible Promissory Note 20
Convertible Notes Payable	$ 227,000
Accrued Interest	$ 8,498

4. Stock Options, Warrants an34

4. Stock Options, Warrants and Restricted Stock Awards (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Granted	0
Warrants, Outstanding	46,000
Warrant, Exercise Price	$ 5
Common Stock
Stock price on the valuation date	$ 0.0254
General and Administrative Expense
Allocated Share-based Compensation Expense	$ 0	$ 28,000
Stock Options
Granted	1,410,000
Fair Value Assumptions, Method Used	Black-Scholes option pricing model
Vesting Period of Award	25 months

4. Stock Options, Warrants an35

4. Stock Options, Warrants and Restricted Stock Awards: Schedule of Stock Options, Activity (Details)	12 Months Ended
	Dec. 31, 2016USD ($)$ / sharesshares
Details
Outstanding, Beginning Balance | shares	1,410,000
Outstanding, Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 0.19
Granted | shares	0
Granted, Weighted Average Exercise Price | $ / shares	$ 0
Exercised | shares	0
Exercised, Weighted Average Exercise Price | $ / shares	$ 0
Forfeited or expired | shares	0
Forfeited or expired, Weighted Average Exercise Price | $ / shares	$ 0
Outstanding, Ending Balance | shares	1,410,000
Outstanding, Weighted Average Exercise Price, Ending Balance | $ / shares	$ 0.19
Outstanding, Weighted Average Remaining Contractual Term	3 years 8 months 19 days
Outstanding, Aggregate Intrinsic Value, Ending Balance | $	$ 0

5. CONVERTIBLE PROMISSORY NOT36

5. CONVERTIBLE PROMISSORY NOTES PAYABLE (Details) - USD ($)

Jul. 27, 2016

Mar. 03, 2016

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2013

Jun. 30, 2016

Dec. 06, 2016

Nov. 08, 2016

Oct. 17, 2016

Sep. 13, 2016

Aug. 05, 2016

Jul. 07, 2016

Jun. 22, 2016

May 19, 2016

Apr. 11, 2016

Mar. 17, 2016

Mar. 14, 2016

Mar. 04, 2016

Feb. 09, 2016

Jan. 04, 2016

Dec. 09, 2015

Nov. 13, 2015

Oct. 13, 2015

Sep. 10, 2015

Aug. 07, 2015

Jul. 13, 2015

Jul. 09, 2015

Jun. 23, 2015

Jun. 22, 2015

May 11, 2015

May 05, 2015

Apr. 17, 2015

Mar. 16, 2015

Feb. 10, 2015

Jan. 14, 2015

Dec. 31, 2014

Dec. 09, 2014

Nov. 07, 2014

Oct. 08, 2014

Oct. 01, 2014

Sep. 09, 2014

Aug. 18, 2014

Aug. 06, 2014

Jul. 18, 2014

Jun. 30, 2014

May 20, 2014

Apr. 18, 2014

Nov. 22, 2013

Oct. 24, 2013

Oct. 21, 2013

Oct. 08, 2013

Sep. 06, 2013

Jun. 04, 2013

May 29, 2013

Mar. 14, 2013

Dec. 31, 2012

Dec. 12, 2012

Adjustments to Additional Paid in Capital

$ 11,630,806

Amortization of debt discount recorded to interest expense

730,545

$ 619,622

Loss (gain) on settlement of debt

33,561

(5,660)

(Loss) gain on settlement of debt

(33,561)

5,660

Series B Preferred Stock | Preferred Stock

Debt Conversion, Original Debt, Amount

1,615,362

Adjustments to Additional Paid in Capital

11,630,806

Principal

Debt Conversion, Original Debt, Amount

10,450

29,200

Loss (gain) on settlement of debt

(5,660)

(Loss) gain on settlement of debt

5,660

Accrued Interest

Debt Conversion, Original Debt, Amount

3,176

6,940

Accrued Interest | Series B Preferred Stock | Preferred Stock

Debt Conversion, Original Debt, Amount

264,530

Convertible Promissory Note 4

Debt Instrument, Face Amount

$ 198,912

$ 299,212

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Convertible, Terms of Conversion Feature

convertible into shares of our common stock at a conversion price equal to (a) the lesser of $0.06 per share or (b) 50% of the lowest trade price recorded on any trade date after the effective date, or (c) the lowest effective price per share granted to any person through the issuance of securities after the effective date.

Convertible Promissory Note 4 | Series B Preferred Stock

Debt Conversion, Original Debt, Amount

$ 71,929

Convertible Promissory Note 4 | Principal

Debt Instrument, Face Amount

291,443

Convertible Promissory Note 4 | Accrued Interest

Debt Instrument, Face Amount

$ 7,769

Convertible Promissory Note 5

Debt Instrument, Face Amount

$ 244,452

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Debt Instrument, Convertible, Terms of Conversion Feature

convertible into shares of our common stock at a conversion price equal to the lesser of $2.00 per share or the closing price per share of common stock recorded on the trading day immediately preceding the date of conversion.

Convertible promissory notes discount

$ 237,742

Convertible Promissory Note 5 | Board of Directors Chairman

Debt Instrument, Face Amount

185,852

Debt Instrument, Maturity Date

Dec. 31, 2016

Description of Embedded Derivative

an option agreement with our principal lender and a principal holder of our Series B preferred stock ('Lender') to acquire 225 shares of our Series B preferred stock from the Lender upon the occurrence of certain events defined in the agreement.

Adjustments to Additional Paid in Capital

$ 325,809

Convertible Promissory Note 5 | Board of Directors Chairman | Derivative Financial Instruments, Liabilities

Extinguishment of Debt, Amount

106,858

Convertible Promissory Note 5 | Principal | Board of Directors Chairman

Debt Instrument, Face Amount

185,852

$ 185,852

$ 185,852

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Extinguishment of Debt, Amount

185,752

Convertible Promissory Note 5 | Accrued Interest | Board of Directors Chairman

Debt Instrument, Face Amount

27,878

18,585

Extinguishment of Debt, Amount

$ 33,199

Convertible Promissory Note 5 | Advance 1

Debt Instrument, Debt Default, Amount

$ 25,980

Convertible Promissory Note 5 | Advance 2

Debt Conversion, Original Debt, Amount

$ 32,619

Debt Instrument, Maturity Date

Dec. 31, 2017

Convertible Promissory Note 6

Debt Instrument, Face Amount

$ 100,000

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Convertible, Terms of Conversion Feature

convertible into shares of our common stock at a price equal to a variable conversion price of the lesser of $0.90 per share or fifty percent (50%) of the lowest trade price recorded after the effective date.

Convertible promissory notes discount

$ 40,000

Debt Instrument, Maturity Date

Jun. 30, 2016

Proceeds from Notes Payable

40,000

Convertible Promissory Note 6 | Series B Preferred Stock | Preferred Stock

Debt Conversion, Original Debt, Amount

$ 34,450

Convertible Promissory Note 6 | Principal | Common Stock

Debt Conversion, Original Debt, Amount

5,550

Convertible Promissory Note 6 | Accrued Interest | Common Stock

Debt Conversion, Original Debt, Amount

1,660

Convertible Promissory Note 6 | Accrued Interest | Series B Preferred Stock

Debt Conversion, Original Debt, Amount

$ 9,607

Convertible Promissory Note 12

Debt Instrument, Face Amount

$ 29,500

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Debt Instrument, Maturity Date

Mar. 14, 2015

Convertible Promissory Note 13

Debt Instrument, Face Amount

$ 97,000

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Convertible, Terms of Conversion Feature

convertible into shares of our common stock at a price equal to a conversion price of the lesser of $0.28 per share or fifty percent (50%) of the lowest trade price recorded after the effective date.

Convertible promissory notes discount

$ 97,000

Debt Instrument, Maturity Date

Jun. 30, 2016

Convertible Promissory Note 13 | Series B Preferred Stock

Debt Conversion, Original Debt, Amount

$ 97,000

Convertible Promissory Note 13 | Accrued Interest | Series B Preferred Stock | Preferred Stock

Debt Conversion, Original Debt, Amount

$ 27,461

Convertible Promissory Note 14 | Director

Debt Instrument, Face Amount

25,000

$ 25,000

$ 25,000

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Debt Instrument, Convertible, Terms of Conversion Feature

convertible into shares of common stock of the Company at a conversion price equal to the lesser of $0.35 per share or the closing price per share of common stock recorded on the trading day immediately preceding the date of conversion.

Debt Instrument, Maturity Date

Jun. 4, 2016

Debt Instrument, Frequency of Periodic Payment

12 equal monthly payments of principal and interest

Periodic Payment Amount

$ 2,352

Convertible Promissory Note 14 | Principal | Director

Long-term Debt, Gross

$ 10,417

Convertible Promissory Note 14 | Accrued Interest | Director

Long-term Debt, Gross

$ 1,328

Convertible Promissory Note 16

Debt Instrument, Face Amount

$ 5,000

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Convertible, Terms of Conversion Feature

convertible into shares of our common stock at a price equal to a conversion price of the lesser of $0.042 per share or fifty percent (50%) of the lowest trade price recorded after the effective date.

Convertible promissory notes discount

$ 2,536

Convertible Promissory Note 17

Debt Instrument, Face Amount

$ 250,000

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Convertible, Terms of Conversion Feature

convertible into shares of common stock of the Company at a price equal to the lesser of $0.06 or 50% of the lowest trade price subsequent to the effective date of the note and prior to the conversion.

Debt Instrument, Maturity Date

Jun. 30, 2016

Convertible Promissory Note 17 | Principal | Series B Preferred Stock | Preferred Stock

Debt Conversion, Original Debt, Amount

58,000

Convertible Promissory Note 17 | Accrued Interest | Series B Preferred Stock | Preferred Stock

Debt Conversion, Original Debt, Amount

13,609

Convertible Promissory Note 17 | Advance 1

Debt Instrument, Face Amount

$ 11,000

Convertible promissory notes discount

$ 11,000

Convertible Promissory Note 17 | Advance 2

Debt Instrument, Face Amount

$ 22,000

Convertible promissory notes discount

$ 22,000

Convertible Promissory Note 17 | Advance 3

Debt Instrument, Face Amount

$ 25,000

Convertible promissory notes discount

$ 25,000

Convertible Promissory Note 18

Debt Instrument, Face Amount

$ 500,000

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Convertible, Terms of Conversion Feature

The note was convertible into shares of our common stock at a price per share equal to the lesser of: $0.03; or 50% of the lowest trade price subsequent to the effective date of the note and prior to the conversion; or the lowest effective price per share granted to any person or entity to acquire common stock subsequent to the effective date of the note.

Convertible Promissory Note 18 | Principal | Series B Preferred Stock | Preferred Stock

Debt Conversion, Original Debt, Amount

500,000

Convertible Promissory Note 18 | Accrued Interest | Series B Preferred Stock | Preferred Stock

Debt Conversion, Original Debt, Amount

82,677

Convertible Promissory Note 18 | Advance 1

Debt Instrument, Face Amount

$ 60,000

Convertible promissory notes discount

$ 60,000

Amortization of debt discount recorded to interest expense

31,861

Convertible Promissory Note 18 | Advance 2

Debt Instrument, Face Amount

$ 45,000

Convertible promissory notes discount

$ 45,000

Amortization of debt discount recorded to interest expense

26,557

Convertible Promissory Note 18 | Advance 3

Debt Instrument, Face Amount

$ 200,000

Convertible promissory notes discount

$ 200,000

Amortization of debt discount recorded to interest expense

132,847

Convertible Promissory Note 18 | Advance 4

Debt Instrument, Face Amount

$ 25,000

Convertible promissory notes discount

$ 25,000

Amortization of debt discount recorded to interest expense

$ 820

16,621

Convertible Promissory Note 18 | Advance 5

Debt Instrument, Face Amount

$ 65,000

Convertible promissory notes discount

$ 65,000

Amortization of debt discount recorded to interest expense

4,381

43,215

Convertible Promissory Note 18 | Advance 6

Debt Instrument, Face Amount

$ 25,000

Convertible promissory notes discount

$ 25,000

Amortization of debt discount recorded to interest expense

2,231

16,621

Convertible Promissory Note 18 | Advance 7

Debt Instrument, Face Amount

$ 56,000

Convertible promissory notes discount

$ 56,000

Amortization of debt discount recorded to interest expense

7,064

37,367

Convertible Promissory Note 18 | Advance 8

Debt Instrument, Face Amount

$ 24,000

Convertible promissory notes discount

$ 24,000

Amortization of debt discount recorded to interest expense

$ 4,336

15,985

Convertible Promissory Note 19

Debt Instrument, Face Amount

$ 500,000

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Convertible, Terms of Conversion Feature

The note was convertible into shares of our common stock at a price per share equal to the lesser of: $0.03; or 50% of the lowest trade price subsequent to the effective date of the note and prior to the conversion; or the lowest effective price per share granted to any person or entity to acquire common stock subsequent to the effective date of the note.

Convertible Promissory Note 19 | Principal | Series B Preferred Stock | Preferred Stock

Debt Conversion, Original Debt, Amount

500,000

Convertible Promissory Note 19 | Accrued Interest | Series B Preferred Stock

Debt Conversion, Original Debt, Amount

50,748

Convertible Promissory Note 19 | Advance 1

Debt Instrument, Face Amount

$ 65,000

Convertible promissory notes discount

$ 65,000

Amortization of debt discount recorded to interest expense

$ 10,912

43,294

Convertible Promissory Note 19 | Advance 2

Debt Instrument, Face Amount

$ 30,000

Convertible promissory notes discount

$ 30,000

Amortization of debt discount recorded to interest expense

7,020

20,018

Convertible Promissory Note 19 | Advance 3

Debt Instrument, Face Amount

$ 25,000

Convertible promissory notes discount

$ 25,000

Amortization of debt discount recorded to interest expense

7,345

16,651

Convertible Promissory Note 19 | Advance 4

Debt Instrument, Face Amount

$ 92,000

Convertible promissory notes discount

$ 92,000

Amortization of debt discount recorded to interest expense

32,965

59,035

Convertible Promissory Note 19 | Advance 5

Debt Instrument, Face Amount

$ 30,000

Convertible promissory notes discount

$ 30,000

Amortization of debt discount recorded to interest expense

12,230

17,770

Convertible Promissory Note 19 | Advance 6

Debt Instrument, Face Amount

$ 30,000

Convertible promissory notes discount

$ 30,000

Amortization of debt discount recorded to interest expense

14,182

15,818

Convertible Promissory Note 19 | Advance 7

Debt Instrument, Face Amount

$ 45,000

Convertible promissory notes discount

$ 45,000

Amortization of debt discount recorded to interest expense

23,852

21,148

Convertible Promissory Note 19 | Advance 8

Debt Instrument, Face Amount

$ 65,000

Convertible promissory notes discount

$ 65,000

Amortization of debt discount recorded to interest expense

36,636

28,364

Convertible Promissory Note 19 | Advance 9

Debt Instrument, Face Amount

$ 40,000

Convertible promissory notes discount

$ 40,000

Amortization of debt discount recorded to interest expense

22,982

17,018

Convertible Promissory Note 19 | Advance 10

Debt Instrument, Face Amount

$ 35,000

Convertible promissory notes discount

$ 35,000

Amortization of debt discount recorded to interest expense

22,760

12,240

Convertible Promissory Note 19 | Advance 11

Debt Instrument, Face Amount

$ 20,000

Convertible promissory notes discount

$ 20,000

Amortization of debt discount recorded to interest expense

13,042

6,958

Convertible Promissory Note 19 | Advance 12

Debt Instrument, Face Amount

$ 23,000

Convertible promissory notes discount

$ 23,000

Amortization of debt discount recorded to interest expense

$ 15,682

7,318

Convertible Promissory Note 20

Debt Instrument, Face Amount

$ 500,000

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Convertible, Terms of Conversion Feature

The note was convertible into shares of our common stock at a price per share equal to the lesser of: $0.03; or 50% of the lowest trade price subsequent to the effective date of the note and prior to the conversion; or the lowest effective price per share granted to any person or entity to acquire common stock subsequent to the effective date of the note.

Convertible Promissory Note 20 | Principal | Series B Preferred Stock | Preferred Stock

Debt Conversion, Original Debt, Amount

227,000

Convertible Promissory Note 20 | Accrued Interest | Series B Preferred Stock | Preferred Stock

Debt Conversion, Original Debt, Amount

$ 8,498

Convertible Promissory Note 20 | Advance 1

Debt Instrument, Face Amount

$ 12,000

Convertible promissory notes discount

$ 12,000

Amortization of debt discount recorded to interest expense

$ 8,269

3,731

Convertible Promissory Note 20 | Advance 2

Debt Instrument, Face Amount

$ 65,000

Convertible promissory notes discount

$ 65,000

Amortization of debt discount recorded to interest expense

47,745

17,255

Convertible Promissory Note 20 | Advance 3

Debt Instrument, Face Amount

$ 25,000

Convertible promissory notes discount

$ 25,000

Amortization of debt discount recorded to interest expense

19,881

5,119

Convertible Promissory Note 20 | Advance 4

Debt Instrument, Face Amount

$ 25,000

Convertible promissory notes discount

$ 25,000

Amortization of debt discount recorded to interest expense

21,389

3,611

Convertible Promissory Note 20 | Advance 5

Debt Instrument, Face Amount

$ 25,000

Convertible promissory notes discount

$ 25,000

Amortization of debt discount recorded to interest expense

22,806

2,194

Convertible Promissory Note 20 | Advance 6

Debt Instrument, Face Amount

$ 25,000

Convertible promissory notes discount

$ 25,000

Amortization of debt discount recorded to interest expense

23,995

$ 1,005

Convertible Promissory Note 20 | Advance 7

Debt Instrument, Face Amount

$ 25,000

Convertible promissory notes discount

$ 25,000

Amortization of debt discount recorded to interest expense

25,000

Convertible Promissory Note 20 | Advance 8

Debt Instrument, Face Amount

$ 25,000

Convertible promissory notes discount

$ 25,000

Amortization of debt discount recorded to interest expense

$ 25,000

Convertible Promissory Note 21

Debt Instrument, Face Amount

$ 1,000,000

Debt Instrument, Convertible, Terms of Conversion Feature

convertible into shares of our common stock at a price per share equal to the lesser of: $0.03; 50% of the lowest trade price of our common stock subsequent to the effective date of the note; or the lowest effective price per share granted to any person or entity (exclusive of our officers and directors) to acquire common stock subsequent to the effective date of the note.

Convertible Promissory Note 21 | Advance 1

Debt Instrument, Face Amount

25,000

Convertible promissory notes discount

$ 4,315

$ 25,000

Amortization of debt discount recorded to interest expense

20,685

Convertible Promissory Note 21 | Advance 2

Debt Instrument, Face Amount

$ 27,000

Convertible promissory notes discount

5,400

$ 27,000

Amortization of debt discount recorded to interest expense

21,600

Convertible Promissory Note 21 | Advance 3

Debt Instrument, Face Amount

$ 33,000

Convertible promissory notes discount

11,392

$ 33,000

Amortization of debt discount recorded to interest expense

21,608

Convertible Promissory Note 21 | Advance 4

Debt Instrument, Face Amount

$ 90,000

Convertible promissory notes discount

24,904

$ 90,000

Amortization of debt discount recorded to interest expense

65,096

Convertible Promissory Note 21 | Advance 5

Debt Instrument, Face Amount

$ 60,000

Convertible promissory notes discount

23,014

$ 60,000

Amortization of debt discount recorded to interest expense

36,986

Convertible Promissory Note 21 | Advance 6

Debt Instrument, Face Amount

$ 50,000

Convertible promissory notes discount

23,699

$ 50,000

Amortization of debt discount recorded to interest expense

36,301

Convertible Promissory Note 21 | Advance 7

Debt Instrument, Face Amount

$ 87,000

Convertible promissory notes discount

44,573

$ 87,000

Amortization of debt discount recorded to interest expense

42,427

Convertible Promissory Note 21 | Advance 8

Debt Instrument, Face Amount

$ 60,000

Convertible promissory notes discount

36,164

$ 60,000

Amortization of debt discount recorded to interest expense

23,836

Convertible Promissory Note 21 | Advance 9

Debt Instrument, Face Amount

$ 55,000

Convertible promissory notes discount

38,575

$ 55,000

Amortization of debt discount recorded to interest expense

16,425

Convertible Promissory Note 21 | Advance 10

Debt Instrument, Face Amount

$ 55,000

Convertible promissory notes discount

43,699

$ 55,000

Amortization of debt discount recorded to interest expense

11,301

Convertible Promissory Note 21 | Advance 11

Debt Instrument, Face Amount

$ 55,000

Convertible promissory notes discount

47,014

$ 55,000

Amortization of debt discount recorded to interest expense

7,986

Convertible Promissory Note 21 | Advance 12

Debt Instrument, Face Amount

$ 60,000

Convertible promissory notes discount

56,233

$ 60,000

Amortization of debt discount recorded to interest expense

$ 3,767

6. Derivative Liabilities_ Fair

6. Derivative Liabilities: Fair Value Inputs, Quantitative Information (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Series B Preferred Stock
Stock price on the valuation date	$ 0.0254
Conversion price for the debt	$ 0.0045
Years to maturity	15 years
Expected volatility	245.30%
Convertible Notes, Current
Stock price on the valuation date	$ 0.0254	$ 0.004
Dividend yield	0.00%	0.00%
Convertible Notes, Current | Minimum
Conversion price for the debt	$ 0.0763	$ 0.004
Years to maturity	2 months 12 days	1 year
Risk free rate	0.51%	0.65%
Expected volatility	115.06%	103.67%
Convertible Notes, Current | Maximum
Conversion price for the debt	$ 0.0045	$ 0.0045
Years to maturity	1 year	1 year 5 months 8 days
Risk free rate	0.85%	0.86%
Expected volatility	189.59%	151.10%

6. Derivative Liabilities (Deta

6. Derivative Liabilities (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Derivative liabilities	$ 6,690,697	$ 13,184,369
Series B Preferred Stock
Derivative liabilities	3,354,791
Convertible Notes, Current
Derivative liabilities	$ 3,335,906	$ 13,184,369

7. Research Agreements and Fo39

7. Research Agreements and Formation of subsidiary (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Jan. 31, 2015
Research and development	$ 65,497	$ 298,865
Transphene, Inc.
Noncontrolling Interest, Ownership Percentage by Parent			50.00%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	50.00%
Sponsored Research Agreement #1
Sponsored Research Agreement Total Cost	$ 387,730
Research and development		$ 193,865
Sponsored Research Agreement #2
Sponsored Research Agreement Total Cost	$ 65,497
Term of SRA 2	The term of SRA #2 commenced on January 1, 2016 and expired on June 30, 2016.

8. Supplemental Statement of 40

8. Supplemental Statement of Cash Flows Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016		Dec. 31, 2015
Income Taxes Paid	$ 0		$ 0
Interest Paid	1,860		0
Issuance of common stock for conversion of notes payable and accrued interest payable, Value	86,387		722,387
Adjustments to Additional Paid in Capital	11,630,806
Increase (Decrease) in Derivative Liabilities	(33,756)		(691,907)
(Loss) gain on settlement of debt	(33,561)		5,660
Chief Executive Officer
Increase (Decrease) in Derivative Liabilities	(106,858)
Series B Preferred Stock
Issuance of common stock for conversion of notes payable and accrued interest payable, Value	1
Increase (Decrease) in Derivative Liabilities	(9,750,930)
Convertible Notes, Non-Current
Adjustments to Additional Paid in Capital			642,074
(Loss) gain on settlement of debt	(39,005)
Issuance Of New Notes During Period
Increase (Decrease) in Derivative Liabilities	707,000		557,000
Increase Decrease in Debt Discount for the Period	707,000		557,000
Principal
Debt Conversion, Original Debt, Amount	10,450		29,200
(Loss) gain on settlement of debt			5,660
Principal | Convertible Notes, Current | Chief Executive Officer
Debt Conversion, Original Debt, Amount	(185,752)
Accrued Interest
Debt Conversion, Original Debt, Amount	3,176		$ 6,940
Accrued Interest | Convertible Notes, Current | Chief Executive Officer
Debt Conversion, Original Debt, Amount	$ (33,199)
Common Stock
Issuance of common stock for conversion of notes payable and accrued interest payable, Shares	3,028,018	[1]	8,031,172	[2]
Issuance of common stock for conversion of notes payable and accrued interest payable, Value	$ 3,028	[1]	$ 8,031	[2]
Debt Conversion, Converted Instrument, Shares Issued	3,028,018		80,311,720
Common Stock | ReverseStockSplitMember
Issuance of common stock for conversion of notes payable and accrued interest payable, Value	$ 1
Debt Conversion, Converted Instrument, Shares Issued	816
Common Stock | Convertible Notes, Non-Current
Issuance of common stock for conversion of notes payable and accrued interest payable, Value			$ 80,313
Adjustments to Additional Paid in Capital	$ 83,359
Preferred Stock
Increase (Decrease) in Derivative Liabilities	$ 3,908,211
Preferred Stock | Series B Preferred Stock
Issuance of common stock for conversion of notes payable and accrued interest payable, Shares	16,155
Debt Conversion, Original Debt, Amount	$ 1,615,362
Issuance of common stock for conversion of notes payable and accrued interest payable, Value	1,615,500
Adjustments to Additional Paid in Capital	11,630,806
Increase (Decrease) in Derivative Liabilities	$ 3,908,211
Debt Conversion, Converted Instrument, Shares Issued	16,155
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt	$ (3,908,211)
Preferred Stock | Accrued Interest | Series B Preferred Stock
Debt Conversion, Original Debt, Amount	264,530
Additional Paid-in Capital
Issuance of common stock for conversion of notes payable and accrued interest payable, Value	83,359		$ 714,356
Additional Paid-in Capital | ReverseStockSplitMember
Issuance of common stock for conversion of notes payable and accrued interest payable, Value	$ (1)
[1]	3,028,018 shares issued at fair value at $0.028 - $0.029 per share
[2]	8,031,172 shares issued at fair value at $0.055 - $0.135 per share

9. Income Taxes_ Schedule of Ef

9. Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Details
Combined U.S. federal and state rate	43.00%
Income tax benefit at statutory rate	$ (119,400)	$ (2,243,800)
State income taxes, net of federal benefit	(300)	(300)
Nondeductible stock deductions	61,900	1,928,300
Other	(12,200)	0
Valuation allowance	70,000	315,800
Income Tax Expense (Benefit), Total

9. Income Taxes_ Schedule of De

9. Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating loss carryforward	$ 3,839,800	$ 3,782,600
Research and development credit carryforward	125,200	100,100
Related party accrued expenses	600	13,400
Accrued compensated absences	900	400
Valuation allowance	(3,966,500)	(3,896,500)
Deferred Tax Assets, Net, Total	$ 0	$ 0

9. Income Taxes (Details)

9. Income Taxes (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Details
Valuation allowance	$ 3,966,500	$ 3,896,500
Operating Loss Carryforwards	$ 8,930,000

10. Related Party Transactions

10. Related Party Transactions (Details) - USD ($)	Jul. 27, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Jun. 04, 2013	Dec. 31, 2012	Dec. 12, 2012
Adjustments to Additional Paid in Capital		$ 11,630,806
Accrued interest, notes payable		50,964	$ 285,624
Preferred Stock | Series B Preferred Stock
Adjustments to Additional Paid in Capital		$ 11,630,806
Chief Executive Officer | Preferred Stock | Series B Preferred Stock
Debt Conversion, Converted Instrument, Warrants or Options Issued	225
Convertible Promissory Note 5
Debt Instrument, Interest Rate, Stated Percentage						5.00%
Debt Instrument, Face Amount						$ 244,452
Convertible Promissory Note 5 | Board of Directors Chairman
Debt Instrument, Face Amount						185,852
Debt Instrument, Maturity Date		Dec. 31, 2016
Payments for Deposits Applied to Debt Retirements	$ 100
Adjustments to Additional Paid in Capital	325,809
Convertible Promissory Note 5 | Board of Directors Chairman | Derivative Financial Instruments, Liabilities
Extinguishment of Debt, Amount	106,858
Convertible Promissory Note 5 | Board of Directors Chairman | Principal
Debt Instrument, Interest Rate, Stated Percentage							5.00%
Debt Instrument, Face Amount			185,852	$ 185,852		$ 185,852
Extinguishment of Debt, Amount	185,752
Convertible Promissory Note 5 | Board of Directors Chairman | Accrued Interest
Debt Instrument, Face Amount			27,878	18,585
Extinguishment of Debt, Amount	$ 33,199
Convertible Promissory Note 14 | Director
Debt Instrument, Interest Rate, Stated Percentage					5.00%
Debt Instrument, Face Amount			25,000	25,000	$ 25,000
Debt Instrument, Maturity Date		Jun. 4, 2016
Accrued interest, notes payable			$ 3,219	$ 1,969
Convertible Promissory Note 14 | Director | Principal
Long-term Debt, Gross		$ 10,417
Convertible Promissory Note 14 | Director | Accrued Interest
Long-term Debt, Gross		$ 1,328

11. Commitments and Contingen45

11. Commitments and Contingencies - Operating Lease (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2013
Operating Leases, Rent Expense			$ 45,646		$ 58,306
Minimum rental payments for the year ended December 31, 2016	$ 35,652
Minimum rental payments for the year ended December 31, 2017	26,739
Operating Lease
Periodic Payment Amount	$ 3,639	$ 3,533		$ 3,450		$ 2,884

12. Consulting Agreements (Deta

12. Consulting Agreements (Details)	12 Months Ended
	Dec. 31, 2013USD ($)
Chief Executive Officer
Consulting Fee, per month	$ 5,000

13. Subsequent Events (Details)

13. Subsequent Events (Details) - USD ($)	1 Months Ended		3 Months Ended	12 Months Ended
	Feb. 28, 2017	Jan. 31, 2017	Mar. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Principal
Debt Conversion, Original Debt, Amount				$ 10,450	$ 29,200
Accrued Interest
Debt Conversion, Original Debt, Amount				$ 3,176	$ 6,940
Common Stock
Debt Conversion, Converted Instrument, Shares Issued				3,028,018	80,311,720
Subsequent Event | Principal
Debt Conversion, Original Debt, Amount			$ 5,000
Subsequent Event | Accrued Interest
Debt Conversion, Original Debt, Amount			$ 1,734
Subsequent Event | Advance 1 | Issuance Of New Notes During Period
Proceeds from Notes Payable		$ 60,000
Subsequent Event | Advance 2 | Issuance Of New Notes During Period
Proceeds from Notes Payable	$ 60,000
Subsequent Event | Common Stock
Debt Conversion, Converted Instrument, Shares Issued			1,496,499

Uncategorized Items - cabn-2016

Label	Element	Value
Common Stock, shares outstanding	us-gaap_CommonStockSharesOutstanding	35,178,624
Common Stock, shares outstanding	us-gaap_CommonStockSharesOutstanding	32,149,790
Preferred Stock, shares outstanding	us-gaap_PreferredStockSharesOutstanding	16,155
Preferred Stock, shares issued	us-gaap_PreferredStockSharesIssued	16,155
Common Stock, shares issued	us-gaap_CommonStockSharesIssued	35,178,624
Common Stock, shares issued	us-gaap_CommonStockSharesIssued	32,149,790